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Abstract 
Parkin is a Parkinson’s disease-linked E3 ubiquitin (Ub) ligase that promotes mitophagy by 
ubiquitination of mitochondrial outer membrane proteins. Phosphorylation of Ub at Ser65 by 
the PTEN-induced putative kinase 1 activates parkin. The role of other Ub phosphorylation 
sites and the associated kinases remain unknown. We optimized genetic code expansion to 
produce pure site-specfically phosphorylated Ub (pUb) variants (pUbS7, pUbS12, pUbS20, 
pUbS65) and investigated their activity in a key neurodegenerative pathway. Purification of 
pUbS7 revealed a +3 frameshifted protein (Ub ∆7) that was successfully purified away from 
the pUb. Parkin was significantly activated when pUbS12 or pUbS65 was the sole parkin 
substrate. pUbS20 showed dose-dependent inhibition of stimulated parkin. Producing pure 
phosphoprotein was essential, as we showed parkin activity is sensitive to the stoichiometry 
and location of phosphorylation on its substrate Ub. Further mechanistic investigations of Ub 
phosphorylation will identify new pathways and potential drug targets in neurodegenerative 
signalling networks.  
Keywords 
Cellular signalling, genetic code expansion, parkin, Parkinson’s disease, phosphorylation, 
phosphoserine, protein degradation, synthetic biology, tRNA, ubiquitin 
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Chapter 1 
1 Introduction 
 Neurodegenerative disorders 
1.1.1 Prevalence of neurodegenerative disorders 
Neurodegenerative disorders are debilitating conditions typified by progressive 
degeneration of certain regions in the brain and deposition of abnormal proteins in cells1. 
Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS or Lou-Gehrig’s disease) 
and Parkinson’s disease (PD) are three of the most common neurological disorders2. 
Reactive oxygen species (ROS) are commonly observed at increased levels in brain tissue 
samples of individuals with AD, ALS and PD. Increased ROS is related to the relatively 
high metabolic and low cellular regeneration rates in the brain3. Protein nitration, often 
associated with oxidation of proteins, is present in greater abundance in the hippocampus 
and neocortex of AD patients, motor neurons of ALS patients and Lewy bodies of PD 
patients4-6. The increased incidence of ROS and lack of cellular regeneration in the brain 
renders these diseases almost incurable. Although there are several lines of cellular 
defense to prevent and repair oxidative damage from ROS, neurodegenerative disorders 
also have reduced activity of antioxidants, such as a glutathione reduction in PD 
patients3.  
The Canadian Institute for Health Information published a report on 11 of the most 
common neurological conditions in Canada: AD, ALS, brain tumours, cerebral palsy, 
epilepsy, head injury, headaches, multiple sclerosis, PD, spinal injuries, and stroke2. In 
the 21st century, the Public Health Agency of Canada estimated the direct costs (i.e., 
treatments and medication) associated with these 11 conditions to be $2.3 billion and 
their indirect costs (i.e., morbidity and mortality) to be $6.5 billion2. Out of the total value 
for indirect costs associated with these diseases, the costs resulting from morbidity made 
up 60% to 80% for AD, cerebral palsy, epilepsy, multiple sclerosis and PD2. A more 
recent report published by the Ontario Brain Institute focused on 13 brain disorders 
similar to the 11 most common neurological conditions, but including motor neuron 
disease, schizophrenia and spina bifida, and excluding ALS7. These brain disorders 
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increased on average by 1.4 per 1000 persons from 2004 to 20107. This increase is 
attributed to longer survival times due to improved clinical care and earlier diagnosis 
from advances in detection methods7. Despite the increased prevalence, effective 
treatments and cures for many of these neurodegenerative diseases are still far from 
reality. Effective therapeutic approaches are essential immediately since the costs 
associated with these neurodegenerative diseases represent a significant burden on the 
Canadian health care system.  
1.1.2 Parkinson’s disease 
PD is the second most common neurodegenerative disorder and predominantly affects the 
older population8. This chronic, progressive disorder is characterized by the loss of 
dopaminergic neurons resulting in tremors and postural instability8. Neurodegeneration 
occurs in the substantia nigra and locus coeruleus of the brain; the presence of 
intracytoplasmic protein aggregates termed Lewy bodies in these regions of the brain 
stem are elevated in patients with idiopathic PD9.  
Autosomal dominant and autosomal recessive inheritance of PD have been 
identified9. A plethora of psychological symptoms can also be observed, such as 
depression, anxiety, psychosis and fatigue8. The dopamine replacement therapy L-DOPA 
(i.e., Levodopa or L-3,4-dihydroxyphenylalanine) was the first drug approved for PD10. L-
DOPA is known to improve individual motor symptoms, but there is a large variation in 
the drug’s effect on the cognitive functions of different PD patients10. Presently, there is 
no cure for PD and treatment options, such as L-DOPA, are only used to control the 
intensity of the symptoms8.  
Several charities, such as Parkinson Society Canada, provide education and advocacy 
to help alleviate the burden for individuals living with PD11. However, this does not 
resolve the persistent need to find a cure for PD. Recent data estimate 0.2% of adults in 
private households and 4.9% of adults in residential care facilities have PD8. From 2011 
to 2031, the number of Canadians over 65 living with PD was predicted to double due to 
an increase in the aging population12. PD patients also had the highest use of prescription 
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medication12. These facts highlight the importance of determining the etiology of PD in 
hopes of finding a cure that eventually leads to elimination of PD prevalence. 
 Protein quality control 
1.2.1 The ubiquitination cascade 
Proteins involved in the ubiquitin proteasome system (UPS) have been shown to play a 
significant role in PD pathogenesis13-16. The UPS is responsible for majority of protein 
turnover within the cell through covalent ligation of the target substrate with ubiquitin 
(Ub), a highly conserved 8.5 kilodalton (kDa) protein with 76 amino acid residues 
(Figure 1.1)17. The highly conserved nature of Ub is evident as human and yeast Ub have 
96% amino acid sequence identity18. There are only 3 amino acid residues that are 
substituted between human and yeast Ub: P19S, E24D and A28S18.  
Protein ubiquitination via the UPS requires the sequential action of three enzymes19. 
The carboxy-terminal (C-terminal) glycine residue (G76) of Ub is activated in an ATP-
Figure 1.1: Generalized schematic of the UPS. E1 Ub-activating enzymes activate Ub in the presence of 
ATP. Ub is then conjugated to the E2 Ub-conjugating enzymes and the E3 Ub ligases catalyze the transfer 
of Ub onto the target substrate. Further reactions allow polyubiquitination of the substrate, which lead to 
subsequent substrate degradation.  
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dependent step by the Ub-activating enzyme named E1. During this step, an intermediate 
Ub adenylate is formed with the release of inorganic pyrophosphate. A thioester linkage 
is subsequently formed between the glycine’s carboxyl group of Ub and the sulfhydryl 
group of a cysteine residue of E1 along with the release of AMP. The E2 Ub-conjugating 
enzyme then catalyzes the transfer of Ub through a transthioesterification reaction from 
E1 to the active site cysteine of E2. The final step of this cascade, transfer of Ub chains to 
substrate proteins, is catalyzed by E3 Ub ligases.  
Bioinformatic identifications, based on protein homology, found 2 E1s, 40 E2s and 
over 600 E3 Ub ligases in the human proteome20. The E3 family of enzymes confer the 
greatest substrate specificity in the UPS and they facilitate the covalent isopeptide linkage 
between the ε-amino group of a lysine residue of the substrate and the C-terminal 
carboxylate group of G76 of Ub20. Further reactions allow formation of polyUb chains on 
the substrate through isopeptide bonds between the terminal G76 residue of each Ub unit 
and a specific lysine residue (most commonly K48) of the previous Ub21.  
The UPS is involved in several cellular processes, including development, apoptosis, 
and antigen processing17. The involvement of the UPS in development is evident through 
a defect in the E3 enzyme E6-AP in patients with Angelman syndrome, a brain 
development disorder17. Likewise, inactivation of the human E2 enzyme HR6B homolog 
in mice causes infertility in male mouse models22. The UPS also plays a role in apoptosis 
induced by γ-irradiation in human lymphocytes as seen by increased Ub gene expression 
and increasingly ubiquitinated nuclear proteins17. Similarly, apoptosis induced by the 
deprivation of nerve growth factor in sympathetic neurons does not occur when the UPS 
is inhibited23. The UPS also processes many major histocompatibility complex class I 
antigens24.  
1.2.2 Parkin, an E3 Ub ligase 
The E3 Ub ligase parkin and the deubiquitinating enzyme (Ub C-terminal hydrolase L1) 
are components in the UPS that are implicated in PD13,14. A substrate for the UPS, α-
synuclein, was also found to associated with PD through autosomal dominant 
inheritance25. During oxidative stress, the E3 Ub ligase parkin directs damaged 
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mitochondria for mitophagy by tagging mitochondrial outer membrane proteins (e.g., the 
mitochondrial Rho GTPase, MIRO1) with polyUb chains26,27. Although endogenous 
parkin is predominantly found in the cytosol, mitochondrial accumulation of parkin was 
observed following treatment of human embryonic kidney (HEK)-293 cells with carbonyl 
cyanide m-chlorophenylhydrazone (CCCP), a mitochondrial uncoupler that induces 
oxidative damage26.  
Parkin localization to the mitochondrial outer membrane was also observed in HeLa 
cells lines overexpressing parkin26. Following translocation to the mitochondrial outer 
membrane, parkin is capable of forming K48-linked polyUb chains as well as K63-linked 
polyUb chains on outer membrane proteins28. The cellular outcome of polyubiquitination 
is dependent on the topology of the polyUb chain linkage. Mitophagy predominantly 
occurs in the presence of polyUb chain linkage by K63 and protein degradation by the 
UPS occurs via K48-linked polyUb chains28. These observations highlight a dual 
molecular function for parkin E3 Ub ligase activity: polyubiquitination of mitochondrial 
proteins recruits cellular components needed for mitophagy and acts as a signal for 
protein degradation28.  
The role of parkin E3 Ub ligase activity in mitophagy suggests the importance of 
parkin in neuronal tissue maintenance29. Not surprisingly, PD-causing mutations in 
parkin could perturb the maintenance of neuronal tissues and could be key drug targets in 
PD29. Initial evidence implicating the role of parkin in PD came from genetic mutation 
studies of park2 (the gene encoding parkin) showing association with autosomal 
recessive juvenile parkinsonism (AR-JP). AR-JP is a familial form of PD typified by 
early age onset13. Loss-of-function mutations in parkin are the primary cause of AR-JP 
since mutations in park2 were identified in 50% of AR-JP patients13,30. Parkin-deficient 
mice also showed clear evidence of mitochondrial dysfunction and oxidative damage, 
two key factors leading to PD31.  Heterozygous mutations of parkin have also been 
implicated in the more common, late-onset form of the disease32,33. Furthermore, parkin 
was shown to function as an E3 Ub ligase involved in neurotoxicity protection during 
stress by promoting protein degradation34-36.  
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Human parkin is a 52 kDa protein with 465 amino acid residues9. It consists of five 
domains: Ub-like (Ubl) (1-76), really interesting new gene (RING) 0 (144-216), RING1 
(228-327), in-between-ring (IBR) (328-377) and RING2 (415-465)37.  The four RING 
domains (including the IBR) of parkin bind two Zn2+ ions each38. To date, there has been 
only one high-resolution structure reported of parkin with all five of its domains and the 
repressor element (REP) (Figure 1.2B)37. However, even this structure does not include 
the entire sequence of full-length parkin. In order to crystallize parkin along with its 
amino-terminal (N-terminal) Ubl domain, the amino acid residues following the Ubl 
domain were truncated and fused to the RING0 domain37. The lack of a full crystal 
structure for parkin was attributed to the highly flexible region between the Ubl and 
RING0 domain of parkin resulting in decreased stability37. Human parkin and rat parkin 
have 85% amino acid sequence identity39. The crystal structure of the truncated human 
parkin is consistent with the full-length 6.5 Å low-resolution crystal structure of rat 
parkin37,40. 
Figure 1.2: Domain organization and crystal structure of parkin. A) Linear domain organization 
of parkin showing structural boundaries. B) The adapted 1.8 Å resolution crystal structure of human 
parkin (PDB: 5C1Z) illustrates the five domains coloured as in A. The repressor element (REP) is 
represented in grey and the eight zinc atoms are represented as yellow spheres.  
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Initially, parkin was reported to be an E3 Ub ligase since it could ubiquitinate several 
substrates, including itself35,36. Unmodified parkin, however, exists in an autoinhibited 
state resulting in weak basal ubiquitination activity for parkin compared to other Ub 
ligases40-42. The autoinhibition is a result of the close proximity of the Ubl domain to the 
E2~Ub conjugate binding site that is blocked by the REP linker40,43. Likewise, the 
interaction between the RING0 and RING2 domain blocks access to the catalytic cysteine 
residue (C431), which also results in parkin autoinhibition40,42. The disease-linked C431F 
substitution disrupts parkin E3 Ub ligase activity in both auto-ubiquitination and 
substrate assays27,44-46. In addition, the recessive nature of AR-JP is linked to parkin auto-
ubiquitination occurring in cis as opposed to trans41. The IBR-RING2 of parkin 
responsible for auto-ubiquitination was inactivated using the disease-linked T415N 
substitution in full-length parkin and supplemented with an IBR-RING2 candidate 
substrate in auto-ubiquitination assays41. These assays prevented auto-ubiquitination of 
full-length parkin, and thus confirmed cis auto-ubiquitination41.  
Parkin belongs to the RING-between-RING (RBR) family of E3 Ub ligases47. 
Traditionally, E3s were classified into two distinct classes based on their structure and 
mechanism: Homologous to E6-AP C terminus (HECT)-type ligases and RING/UBOX-
type ligases47. HECT domains are bilobal and found only at the C-terminal of proteins47. 
The N-terminal lobe binds the E2 and C-terminal contains the catalytic cysteine residue47. 
RING domains are globular and can be readily identified by a canonical spacing of 
conserved cysteine and histidine residues, which bind two Zn2+ ions to stabilize the 
overall domain structure and allow interaction with E2~Ub conjugates48.  
HECT-type ligases and RING/UBOX-type ligases have different mechanisms of 
action and differ in the enzyme responsible for the aminolysis reaction, which involves 
the transfer of Ub onto the lysine residue of a substrate47. For reactions catalyzed by 
HECT-type ligases, the E3 is responsible for the aminolysis, whereas the E2 is 
responsible in reactions catalyzed by RING/UBOX-type ligases47. The RBR family that 
parkin belongs to is a hybrid between the HECT- and RING/UBOX-type ligases. RBR 
family E3 ligases have a N-terminal with a RING-type E2 binding domain and a C-
terminal active site47. Unlike RING domains, RBR domains can be found at any location 
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on their respective proteins47. The RBR family of E3 ligases consists of 15 proteins from 
which parkin is functionally the best characterized49. Post-translational regulation and 
autoinhibition are key characteristics of this family of E3 ligases, and parkin is no 
exception47. Pathogenic parkin mutations disrupt the autoinhibition resulting from the 
interaction of the Ubl domain with the RBR region in parkin43. Disruption in parkin 
autoinhibition leads to constitutively active parkin43. We speculate that constitutively 
active parkin could lead to premature degradation of parkin. Constitutively active parkin 
may auto-ubiquitinate itself, and thus signal for its own degradation by the UPS before 
parkin reaches the mitochondria. Premature parkin degradation is expected to inhibit 
mitophagy. 
 Post-translational modifications 
1.3.1 Parkin 
Parkin was initially found to be S-nitrosylated in vivo in PD mouse models and PD 
patient brain tissue samples50,51. S-nitrosylation is a post-translational modification 
(PTM) that inhibits parkin E3 Ub ligase activity, and diminishes subsequent substrate 
ubiquitination and the neuroprotective function of parkin50,51. Three cysteine residues 
(C59, C95 and C182) on parkin were also observed to undergo S-sulfhydration, leading 
to an increase in parkin E3 Ub ligase activity52. Decreased S-sulfhydration and increased 
S-nitrosylation have been observed in PD patient brain samples, which is consistent with 
the respective impact of these modifications on parkin activity50-52. A less recognized 
PTM called neddylation occurs on parkin and increases its E3 Ub ligase activity by 
enhancing its interaction with E2 enzymes and substrates53,54. Parkin can also be 
phosphorylated to increase or decrease its activity55-57.  
1.3.2 Ubiquitin 
The parkin substrate Ub can itself be modified58. Proteomic and chromatographic studies 
have identified Ub acetylation, deamidation and phosphorylation sites in human cells58. 
Acetylation of Ub at either of two specific lysine residues (K6 or K48) disrupts polyUb 
chain elongation linked by K11, K48 (predominantly seen in the UPS) and K6359. 
Acetylated Ub can be transferred onto the E1 and E2 enzymes in the UPS, but blocks the 
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final step of the pathway where Ub chains are transferred to substrate proteins to target 
them for degradation59. Mass spectrometric evidence identified Ub acetylation in vivo 
where 0.03% and 0.01% of total Ub in cells was acetylated on K6 and K48, 
respectively59. Deamidation is the irreversible conversion of an amide to an acid and this 
is another PTM that can occur on Ub60. Ub is deamidated at a glutamine residue (Q40) to 
generate a glutamic acid residue (E40) in its place by the cycle inhibiting factor homolog 
in Burkholderia pseudomallei also known as CHBP60. This single amino acid substitution 
blocks discharge of Ub from the E2 to the E3 in the UPS, but does not affect the 
formation of E1~Ub or E2~Ub conjugates60. 
Phosphorylation of Ub is known to occur at several conserved amino acid residues: 
T7, T12, T14, S20, S57, Y59 and S6558,61 (Figure 1.3). In addition to proteomics, Ub 
phosphorylation has been detected by phospho-specific antibodies in the case of Ub 
phosphorylated at S65 (pUbS65)61. All of the experimentally identified phosphorylation 
sites on Ub are strictly conserved from human to yeast58. In addition, phosphorylation of 
Ub was observed at T7, S20, S57 and S65 in mouse as well as S20 and S57 in rat61. For 
all of these sites, except S65, the respective kinases and phosphatases remain unknown58. 
In addition, the molecular function and abundance in cells of phosphorylated Ub (pUb) 
species have yet to be defined in all cases except for pUbS20 and pUbS65 58,62.  
 
 
 
 
 
 
Figure 1.3: Crystal structure of Ub with locations of observed phosphorylation sites. The serine and 
threonine phosphorylation sites of human Ub (PDB: 1UBQ) are indicated: T7, T12, T14, S20, S57 and 
S65. The lysine residue (K48) most responsible for polyUb chain linkage in the UPS is also indicated. 
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 Phosphorylation 
1.4.1 Activating parkin with phosphorylation 
It has been recently discovered that upon mitochondrial membrane potential 
depolarization, phosphatase and tensin homologue deleted on chromosome 10 (PTEN)-
induced putative kinase 1 (PINK1) is responsible for phosphorylation of parkin at a 
particular serine residue (S65) located in the Ubl domain of parkin57. Phosphorylation at 
S65 of parkin leads to a release of autoinhibition and subsequent activation of the E3 Ub 
ligase activity57. PINK1 also phosphorylates the homologous site, S65, in the substrate 
Ub to stimulate parkin activity63-66.  
Analysis of phosphopeptides using mass spectrometry enabled identification of 
pUbS65 in mitochondria isolated from wild-type cells, but not from PINK1 knockout cells 
following oxidative stress induced by CCCP treatment63. A 14-fold enrichment of pUbS65 
was observed in HEK-293 cells overexpressing active PINK1 as opposed to HEK-293 
cells with kinase-inactive PINK164. In addition to the phosphorylation of single Ub 
molecules, PINK1 can also phosphorylate Ub in polyUb chains66. In addition, optimal 
activation of parkin is only evident in the presence of PINK1-mediated phosphorylation 
of S65 in both parkin and Ub63-65,67. Although the detailed mechanism of parkin 
activation has yet to be completely defined, several groups have presented insightful yet, 
in some cases, contradictory studies on the mechanism of parkin activation and polyUb 
chain building.  
One proposed mechanism is that PINK1 phosphorylates parkin and Ub, which then 
proceeds to alleviate autoinhibition to stimulate parkin leading to a feed-forward model 
of parkin activation63,65. On the contrary, other studies suggested phosphorylation of 
parkin primes the enzyme for activation by pUbS65 64,67. It has also been suggested that 
phosphorylation of parkin by PINK1 occurs following parkin interaction with pUbS65 that 
is present in the mixture of polyUb chains on mitochondrial outer membrane proteins67. 
This secondary recruitment of parkin is thought to directly activate parkin and enhance 
ubiquitination of mitochondrial outer membrane proteins with less specificity than 
phosphorylated parkin67. The phosphorylation of parkin following interaction with 
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pUbS65 could also enhance phosphorylation of parkin since parkin and PINK1 would be 
in close proximity67.  
Accelerated discharge of E2 was also observed in the presence of pUbS65 as well as 
in the presence of parkin phosphorylated at Ser6527,65,66. Isothermal titration calorimetry 
experiments have revealed that pUbS65 binds to full-length parkin with greater than a 100-
fold increase in binding affinity than the interaction between Ub and parkin37,68. In 
addition, the binding affinity between parkin phosphorylated at Ser65 and pUbS65 is about 
10 times stronger than that between unmodified parkin and pUbS65 37,68.  
Phosphorylation of parkin has also been found to be important in substrate 
ubiquitination27. Parkin tags MIRO1 with polyUb chains at highly conserved lysine 
residues (K153, K230, K235, K330 and K572) following phosphorylation at Ser6527. 
PolyUb chain formation on MIRO1 targets the protein for degradation, which is an 
important route to mitophagy26,27. Mitophagy reduces mitochondrial oxidative stress and 
promotes cell survival. Without the clearance of damaged mitochondria in the brain, ROS 
will accumulate as seen in PD patients. It is interesting to note that a cohort of studies 
regarding pUbS65 63-66 only emerged following the discovery of its upstream kinase, 
PINK169.  
The use of phosphomimetics in Ub and parkin (S65D/E) to study the mechanism of 
parkin activation was ultimately misleading67. In vitro biochemical studies showed 
phosphomimetic mutations at S65 in Ub led to a loss of function, while ample evidence 
demonstrate pUbS65 stimulates parkin activity62-67. Proteomics is highly valuable and 
indispensable at identifying phosphorylation sites, but these methods do not measure 
enzymatic activity and insight into signalling mechanisms is limited to correlative 
studies. Biochemical and biophysical approaches with pure pUb variants, when combined 
with data from correlative and cell-based studies will provide a complete description of 
the function and impact of specific Ub phosphorylation events.  
1.4.2 Site-directed phosphorylation of Ub 
In addition to pUbS65, there are 6 other experimentally verified phosphorylation sites on 
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Ub (T7, T12, T14, S20, S57 and Y59) for all of which the upstream kinases remain 
unknown58,61. The function of Ub phosphorylated at these sites and their effect of UPS 
activity has yet to be determined. A major impediment to the elucidation of the function 
of Ub phosphorylation sites is the inability to produce site-specifically phosphorylated 
Ub variants. Due to the lack of knowledge on their respective kinases, there is a pressing 
need for alternate techniques to produce site-specifically phosphorylated Ub at all 
identified phosphorylation sites.  
Genetic code expansion strategies enable production of site-specifically 
phosphorylated proteins in Escherichia coli (E. coli) and is an effective method to 
produce phosphoproteins70. Phosphoprotein production using genetic code expansion 
strategies is especially valuable when the upstream kinase is unknown or difficult to 
obtain. There are more than 100,000 experimentally observed phosphorylation sites; for 
more than 90% of these sites, the upstream kinase remains unknown61,71. The site-specific 
phosphorylation method optimized here reassigns the UAG stop codon to O-phospho-L-
serine (pSer)70. A system for site-specific incorporation of phosphothreonine has yet to be 
developed. Since threonine and serine residues only differ by one methyl group, pSer 
incorporation at these positions will provide more accurate mechanistic insight than 
phosphomimetic mutants.  
The pSer system consists of a pSer-accepting transfer RNA (tRNASep), its cognate 
phosphoseryl-tRNA synthetase (SepRS) and engineered elongation factor (EF)-Tu 
(EFSep)70,72. Mutation of the bacterial EF-Tu to EFSep to bind the tRNASep charged with 
pSer was required to enable translation with pSer70. EFSep was engineered by identifying 
6 mutations in EF-Tu that removed two negative charges in EF-Tu and introduced one 
positively charged amino acid to the binding pocket of EF-Tu: H67R, E216N, D217G, 
F219Y, T229S and N274W70. This changed the charge and shape of the aminoacyl-tRNA 
recognition pocket so that the negatively charged pSer-tRNASep can be accommodated in 
protein synthesis. 
Further mutations to enhance the pSer system and potentially overcome previously 
inefficient pSer incorporation led to the development of SepRS9 and EFSep21 (Figure 
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1.4)73. SepRS9 was constructed by introducing 4 mutations in the anticodon-binding 
domain (E412S, E414I, P495R and I496R) and 3 additional spontaneous mutations 
(K347E, N352D and L512I) in SepRS73. EFSep21 was constructed by introducing the 
substitution mutation N216V in EFSep73. This improved system was expressed in 
BL21(DE3) and produced 3 mg·L-1 E. coli culture of recombinant pSer-containing 
histone H373. 
1.4.3 Competition and mistranslation at UAG 
Another important feature of the pSer system is the use of orthogonal aminoacyl-tRNA 
synthetase:tRNA pairs (i.e., SepRS:tRNASep)70. As with most genetic code expansion 
strategies, an amber suppressor (UAG-decoding) tRNA is used and this enables 
reassignment of the UAG stop codon to pSer70. A limitation to orthogonal translation is 
low protein yield due to competition between peptide chain elongation with the 
aminoacylated suppressor tRNA and termination by release factor 1 (RF1)70.  
This competition was overcome by the use of a RF1 deficient E. coli strain where all 
genomic TAG terminating coding sequences were replaced with synonymous TAA using 
a genome editing technique74-78. Although the newly engineered E. coli strain had an 
increased pSer incorporation efficiency per cell, it was found to be deleterious to cell 
fitness and viability as seen by increased doubling time and decreased final cell 
density76,79.  
Figure 1.4: The incorporation of pSer using genetic code expansion. The UAG codon in Ub is 
reassigned to pSer in E. coli in the presence of SepRS9, EFSep21 and tRNASep. 
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A common misconception associated with genetic code expansion strategies (i.e., the 
pSer system) is that amber codon translation has the same fidelity as the canonical protein 
synthesis80. Using a novel approach that facilitated characterization of organisms with 
expanded genetic codes, the incorporation of noncanonical amino acids (ncAAs) and 
natural amino acids at UAG in a recombinant green fluorescent protein (GFP) was 
detected in the pSer system80. This method also identified mistranslation as a common 
by-product of the pSer system in RF1 deficient E. coli80. Near-cognate mis-incorporation 
of glutamine was most commonly observed with evidence of lysine, tyrosine and 
glutamic acid mis-incorporation in lower abundance than pSer80. The absence of RF1 is 
thought to be a major contributor to increased levels of mistranslation62,80. In a newly 
designed plasmid containing 5 copies of tRNASep, this mistranslation was observed to a 
lesser degree and pSer incorporation was found to be the most abundant80. Using the 
most efficient pSer system (SepRS9/tRNASep and EFSep21) in RF1 deficient E. coli did 
not eliminate this mistranslation, but greater yields of pSer per litre of E. coli culture 
were produced compared to previously tested systems using SepRS/tRNASep and EFSep 
with recombinant GFP81. Although a higher yield of pSer was obtained using 
SepRS9/tRNASep and EFSep21, Phos-tag gels show evidence of non-phosphorylated 
protein present in the mixture81. In addition to mass spectrometry, we found that Phos-tag 
gels are an efficient and effective tool to determine the presence and purity of 
phosphorylated proteins. The gel system relies on the binding of a divalent metal ion 
(Mn2+ or Zn2+) to Phos-tag acrylamide, a proprietary reagent82,83. The divalent metal ion 
can bind to phosphate groups on proteins and retard their migration rate on gels82,83. An 
important factor that is often overlooked in proteins encoding ncAAs is the purity of the 
sample. Due to significant levels of mistranslation, careful consideration should be placed 
on yields reported as this could reflect total protein yield (including mistranslated 
products) as opposed to pure ncAA-containing protein yield.  
 Scope of thesis 
1.5.1 Rationale 
There are many traditional methods that have been used to investigate the effects and 
function of phosphorylation in vivo, in cell culture models and in vitro84. Genetic 
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methods are often used to either disable or mimic phosphorylation. Proteins with alanine 
mutations at known phosphorylation sites are unable to be phosphorylated at the site of 
the alanine mutation. Aspartic acid and glutamic acid residues are commonly used as 
phosphomimetic substitutions due to the single negative charge and somewhat similar 
structure to pSer. Despite their chemical structure similarity, it is not clear that 
phosphomimetics accurately mimic phosphorylation. In one example, the glutamic acid 
mutant of the mitogen-activated ERK activating kinase 1 reveals >70-fold lower activity 
when compared to a true pSer residue70. Though alanine mutant and phosphomimetic 
substitution experiments provided important data and are useful probes of signalling 
pathways, they are often unable to isolate and characterize the molecular role of a 
specific phosphorylation or of multiple phosphorylations in specific combinations or 
stoichiometry.  
The ability to produce designer phosphoproteins in vitro allows precise control over 
the stoichiometry of phosphorylation and provides biochemical, structural and 
mechanistic insights into the activity of these phosphoproteins. Using in vivo studies to 
determine the mechanism of action is complicated by interacting cellular proteins and 
other PTMs in cells. Cell-based studies are often correlative, and complementary 
biochemical studies are needed to provide a detailed mechanistic description of 
phosphoprotein function. The many confounding variables in vivo make it complicated to 
identify interactions between individual proteins, a crucial aspect in exploring the 
biological functions of proteins.  
Since most of the phosphorylation sites on Ub are associated with unidentified 
kinases, genetic code expansion is an ideal strategy to produce otherwise inaccessible 
phosphoproteins. The efficiency of producing pSer in great abundance using the pSer 
system in vitro with SepRS9/tRNASep and EFSep21 makes this system an effective tool. 
Here, we use this method to study the effect of pUb variants on parkin E3 Ub ligase 
activity by site-specifically incorporating pSer at experimentally verified phosphorylation 
sites on Ub58,61.  
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1.5.2 Hypothesis 
In addition to the previously identified pUbS65, I hypothesize that parkin can be 
stimulated by other pUbs (i.e., pUbS12 and pUbS20). My hypothesis will be tested by 
producing pure site-specifically phosphorylated Ub using the pSer system and measuring 
the effect of the pUb variants on parkin activity in auto-ubiquitination assays.  
1.5.3 Findings and significance  
In this thesis, phosphorylated Ub was produced for the first time in high yield and high 
purity. Production of pUb variants using the pSer system in release-factor deficient E. 
coli cells revealed a new by-product of mistranslation where the in-frame UAG codon 
was skipped resulting in a novel phenomenon called codon skipping. This is the first 
published report of +3 frameshift.  
The precise stoichiometric measurements of pUbs needed to stimulate parkin E3 Ub 
ligase activity were also investigated. Using molecular biology and biochemical 
techniques, the work presented in this thesis has advanced the molecular understanding of 
the effect of pUb on parkin activation and identified new roles for different pUbs in the 
activation of parkin E3 Ub ligase activity. The ability to precisely modulate the activity 
of parkin, as we have demonstrated here, will have implications for novel strategies to 
treat PD. 
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Chapter 2 
2 Generation of phospho-ubiquitin variants by orthogonal translation 
reveals codon skipping  
The activity of the Parkinson’s disease (PD)-linked E3 ubiquitin (Ub) ligase parkin is 
stimulated by phosphorylation of ubiquitin at Ser65 (pUbS65). The role of other Ub 
phospho-sites and their kinases are unknown. We produced phosphorylated Ub (pUb) 
variants (pUbS7, pUbS12, pUbS20, pUbS57, pUbS65) by genetically encoding O-phospho-L-
serine with the UAG codon. In release factor 1-deficient (ΔRF1) Escherichia coli (E. 
coli), intended to enhance UAG read-through, we discovered Ub variants lacking the 
UAG-encoded residue, demonstrating previously undocumented +3 frameshifting. We 
successfully purified each pUb variant from mistranslated products. While pUbS20 failed 
to stimulate parkin, parkin was partially active with pUbS12. We observed significant 
ubiquitination when pUbS65 was the only Ub variant in the reaction. 
 Introduction 
In oxidative stress, the E3 Ub ligase parkin is recruited to mitochondria to tag several 
outer membrane proteins (i.e., Miro-1, Miro-2) with Ub chains that signal protein 
degradation and initiate mitophagy1. The role of parkin in clearing defective 
mitochondria is disrupted in PD patients, and the inability for PD-linked mutants to 
achieve normal levels of mitochondrial degradation is thought to contribute to PD2. 
The parkin substrate Ub was recently found to have at least seven experimentally 
observed phosphorylation sites in human cells3-6. As a result of the discovery of an 
upstream kinase, phosphatase and tensin homologue deleted on chromosome 10 (PTEN)-
induced putative kinase 1 (PINK1)7, specific for Ub Ser65, a series of studies followed 
that show phosphorylation at Ser65 in Ub stimulates parkin auto-ubiquitination activity8-
12. In genetic studies, expression of the mutant Ub Ser65Ala reduced poly-Ub chain 
synthesis and mitophagy in osteosarcoma cells10. The role of other Ub phosphorylation 
sites and the associated kinases are unknown2.  
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Genetic code expansion with pSer in E. coli enables biosynthesis of site-specifically 
phosphorylated recombinant protein by reassigning the UAG codon to pSer13. The system 
requires a phosphoseryl-tRNA synthetase (SepRS), derived from an archaeal pathway for 
Cys-tRNACys synthesis, a mutant pSer-accepting transfer RNA (tRNASep)14, and a mutant 
elongation factor (EFSep)13. The pSer system is toxic to normal E. coli strains and initial 
experiments showed phosphoprotein production was possible but inefficient (~1 µg·L-1 
culture)15. When the pSer system is expressed in a ΔRF1 E. coli strain that lacks all 
genomic TAG codons16, improved phosphoprotein production was observed15,17. The 
phosphoprotein was, however, contaminated by incorporation of natural amino acids as a 
result of near-cognate UAG decoding17, limiting the use of this approach where purified 
phosphoproteins are required, especially for preparative biochemical experiments. We 
optimized phosphoprotein expression and purification to efficiently generate and purify 
multiple pUb variants. We conducted an initial examination of parkin E3 Ub ligase 
activity in vitro with purified pUb variants that allowed us to precisely control the 
stoichiometry of phosphorylation in the Ub substrate pool. 
 Materials and Methods 
2.2.1 Bacterial strains and plasmids 
Recombinant proteins were expressed in BL21(DE3) (Invitrogen, Carlsbad, CA, USA), 
or in E. coli ∆RF1 (C321.∆A.exp, Addgene 49018) as specified. The 1st generation pSer 
system is on the plasmid pKD-pSer1 (Addgene 52054) and the 2nd generation system is 
on the plasmid pDS-pSer2 (see Section 2.6.1). The Ub constructs were expressed from 
pDS0-Ub (see Section 2.6.1).  
2.2.2 Phosphoprotein production and purification 
Either pKD-pSer1 or pDS-pSer2 and a pDS0-Ub expression plasmid were freshly 
cotransformed into E. coli ∆RF1 (i.e., C321.∆A.exp16) or BL21(DE3) cells on selective 
media and grown as specified in Section 2.6.1. Cells were harvested and resuspended in ~ 
10 mL wash buffer (50 mM Tris-HCl, 200 mM NaCl, 0.25 mM TCEP, 50 mM NaF, 2 
mM NaVO3, 25 mM imidazole, pH 8.0) per litre culture. 1 mM phenylmethylsulfonyl 
fluoride (PMSF) and 1 tablet of ethylenediaminetetraacetic acid (EDTA)-free mini 
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protease inhibitor cocktail (Roche, Mississauga, ON, USA) were added to the cells. Cells 
were lysed using an EmulsiFlex-C5 homogenizer (Avestin, Ottawa, ON, Canada), 
centrifuged at 41,000 xg to remove cell debris, and filtered through a 0.45-µm filter for 
use on a gravity column or an AKTA Pure L1 fast protein liquid chromatography (FPLC) 
system (GE Healthcare, Little Chalfont, UK) (see Section 2.6.1). To eliminate 
contaminating high molecular weight proteins, fractions were subjected to a Superdex75 
gel filtration column (GE Healthcare) pre-equilibrated in 25 mM HEPES, 100 mM NaCl, 
0.25 mM TCEP pH 7.0. The pUb was then purified from unphosphorylated Ub using ion-
exchange chromatography (see Section 2.6.1). 
2.2.3 In vitro auto-ubiquitination assays  
All reactions contained 0.1 µM E1 (Uba1 – see Section 2.6.1), 1 µM E2 (UbcH7), 1 µM 
E3 (parkin), 5 mM ATP, and a 20-µM final concentration of Ub and/or pUb in a 20-µL 
final reaction volume incubated at 30°C for 1 h. The reaction buffer contained 5 mM 
MgCl2 and 50 mM HEPES pH 7.4. Reactions were quenched with sodium dodecyl 
sulfate (SDS)-loading buffer and subjected to immunoblotting using anti-parkin primary 
antibody (kind gift from Dr. Michael Schlossmacher, University of Ottawa) and 
fluorescent-labelled secondary antibody (Mandel Scientific, Guelph, ON, Canada). Blots 
were visualized using the Li-COR® Odyssey Infrared Imaging System. 
 Results  
2.3.1 Efficiency of phosphoprotein biosynthesis 
Genetic code expansion has relied on using stop codons (normally UAG) to insert 
noncanonical amino acids (ncAAs) into proteins. Competition with release factor 1 (RF1) 
is a limiting factor that depresses ncAA-containing protein yield18. Several groups have 
engineered ΔRF1 E. coli strains to enhance UAG translation efficiency15,16,19-21. We 
quantified pSer incorporation in two E. coli strains. A plasmid (pKD-pSer1) bearing the 
1st generation pSer system (SepRS, EFSep and five tRNASep expression cassettes) was 
coexpressed with a wild-type green fluorescent protein (GFP) reporter or GFP with a 
UAG codon at position 17. In BL21(DE3), we achieved 13% translational read-through 
of the UAG codon with pSer compared to normal sense codon translation (100%) (Figure 
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2.1). Background translation of the UAG codon in the absence of the pSer system in this 
strain is minimal (5%).  
The same constructs were expressed in the ΔRF1 E. coli strain C321.ΔA.exp, in 
which all 321 genomic TAGs were mutated to TAA16. This strain shows sense codon-like 
readthrough of the UAG codon when the pSer system is expressed (Figure 2.1). In the 
absence of the pSer system, natural aminoacyl tRNA with near-cognate anticodons 
decode UAG leading to 60% read-through (Figure 2.1). Although the ΔRF1 E. coli 
produces phosphoprotein efficiently per cell, contamination with natural amino acids 
impedes pure phosphoprotein synthesis17,22. 
 
Figure 2.1: Efficiency of UAG translation with 
pSer in (A) E. coli BL21(DE3) compared to (B) E. 
coli ΔRF1 (C321.ΔA.exp). In both panels, 
fluorescence per cell (GFP Fluorescence/OD600) 
corresponding to wild-type GFP expression (GFP 
WT), coexpression of the 1st generation pSer system 
with GFP containing a UAG codon at position 17 
(GFP UAG17+pSer), expression of the GFP UAG17 
variant without the pSer system (GFP UAG17-pSer), 
and background fluorescence (gray dashed line) from 
cells not expressing GFP (-GFP) are shown. 
2.3.2 Impact on growth from expanding the genetic code with pSer 
Expression of the pSer system in common E. coli strains, such as BL21(DE3), leads to 
significant growth defects15. The pSer system is intended to direct incorporation of pSer 
at a UAG codon in a recombinant protein transcript, but this is not the only UAG codon 
in the transcriptome. There are 321 E. coli genes that terminate protein synthesis with a 
UAG codon, and pSer is incorporated in at least some of the corresponding protein 
products that are then unnaturally extended to the next stop codon15. This unnatural 
protein extension is thought to lead to the observed phenotypic growth defects.  
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The E. coli ΔRF1 strain used here (Figure 2.1B) lacks all genomic TAG codons16. 
Unnatural protein extension induced by the pSer system expression should be totally 
eliminated in this strain, which we hypothesized would in turn eliminate the growth 
defect. We measured the growth of several E. coli ΔRF1 strains transformed with either 
empty plasmids or with a GFP-expressing plasmid (wild-type or UAG17) and with or 
without coexpression of pSer system components (Figure 2.2). In all strains tested, 
addition of the free amino acid pSer stimulated growth and led to higher final cell 
densities.  
Interestingly, cells expressing an incomplete pSer orthogonal translation system (i.e., 
lacking tRNASep or lacking SepRS/EFSep) showed similar doubling times, but with a 
sharply reduced duration of the exponential phase and a maximal cell density that was 
50% less than E. coli ΔRF1 cells expressing a complete pSer system (Figure 2.2). In 
comparing E. coli ΔRF1 to strains expressing GFP and the complete pSer system, the 
growth curves and doubling times are essentially identical. Thus, the growth defects 
Figure 2.2: Impact of genetic code expansion with pSer on bacterial growth in E. coli ΔRF1. (A) 
Growth curves are shown for E. coli ΔRF1 strains expressing the indicated GFP constructs with the 
specified components of the 1st generation pSer system. (B) Growth statistics for E. coli ΔRF1 expressing 
indicated components of the pSer system include: doubling time (top), maximal OD600 (middle), lag time 
(bottom). 
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observed upon expressing the pSer system in E. coli BL21(DE3)15 were mostly 
eliminated in E. coli ΔRF1. 
2.3.3 Characterization of purified pUb 
pUbS65 was produced by the coexpression of the Ub-UAG65 construct with the 1st 
generation pSer system in E. coli ΔRF1. Following His6-tag affinity chromatography, the 
Ub variant was analyzed by electrospray ionization mass spectrometry (ESI-MS) (Figure 
2.3A). Two major mass peaks were observed corresponding to two full-length protein 
products: one with pSer65 (pUbS65) and one with Gln65. This protein mixture was further 
purified using ion-exchange chromatography, which showed the two well-defined peaks, 
consistent with the two mass peaks observed (Figure 2.3B). The identity of pUbS65 was 
assessed by MS/MS (Figure 2.3C) and by Phos-tag gels23, which retard phosphorylated 
proteins so that a band-shift separates unphosphorylated Ub from pUb (Figure 2.4). As a 
comparison to genetically encoded pUbS65, pUb was also produced starting with 
unmodified Ub that was then phosphorylated with the upstream kinase PINK1 (pUbS65-k). 
The enzymatically phosphorylated Ub was separated from the reaction components and 
unreacted Ub by ion-exchange chromatography resulting in homogenous and pure 
pUbS65-k (Figure 2.4A). The purified genetically encoded pUbS65 shows the same band-
shift without evidence of unphosphorylated Ub in the final ion-exchange fraction (Figure 
2.4B). Tryptic digests of the ion-exchange chromatography fractions were further 
analyzed by MS/MS (Figure 2.3C), confirming unambiguously the homogenous 
purification of pUbS65 at a yield of 11 µg·L-1 E. coli culture (Table S2.1).  
2.3.4 Optimization of pUbS12, pUbS20, pUbS57, and pUbS65 production 
Parkin is also phosphorylated by PINK1 in its amino-terminal Ub-like (Ubl) domain at 
Ser6524,25. Expression of the Ubl domain with pSer65 (pUblS65) leads to similar purity 
(Figure S2.8) and yield (Table S2.1) as observed for pUbS65 produced with the 1st 
generation pSer system in E. coli ΔRF1. Other pUb variants (pUbS7, pUbS57) were also 
produced with the 1st generation pSer system in E. coli ΔRF1 and purified to 
homogeneity (Figure S2.9A,B), yet the yield was < 1 µg·L-1 E. coli culture (Table S2.1). 
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To enhance production of different pUb variants, we introduced 2nd generation pSer 
system mutations26 into the pKD-pSer1 plasmid to yield pDS-pSer2. This pSer insertion 
system is more efficient and able to compete against RF126, so the protein production 
host was switched to BL21(DE3). Because near-cognate decoding of UAG is minimal in 
Figure 2.3: Purification of genetically 
encoded pUbS65 from ΔRF1 E. coli. (A) Full-
length protein ESI-MS indicates full-length 
protein products with Gln or pSer at position 
65. (B) Ion-exchange chromatogram shows 
distinct separation of phosphorylated from 
unphosphorylated protein products. (C) 
MS/MS of tryptic-digested pUb run in 
positive ion mode (+0.1% formic acid) 
confirms identity of pure Ub phosphorylated 
Ser65 (s). 
Figure 2.4: Comparison of the purity of kinase phosphorylated (A) and genetically encoded (B-D) 
pUb variants. (A) Preparation of pUbS65 with the upstream kinase PINK1 is shown on a Phos-tag gel; 
unmodified Ub (lane 1), PINK1 phosphorylated and purified pUbS65 (lane 2). (B) Fractions from ion-
exchange chromatography (e.g., Figure 2.3B) that separated the contaminant Ub Gln65 (lanes 1 and 2) and 
pure genetically encoded pUbS65 (lane 3). (C) Ion-exchange chromatography fractions of mistranslated 
(unphosphorylated) Ub (lanes 1 and 2) from His6-pUbS20 (lanes 3 and 4). (D) Ion-exchange 
chromatography fractions of mistranslated (unphosphorylated) Ub (lanes 1 and 2) separated from pure 
His6-pUbS12 (lanes 3 and 4). 
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BL21(DE3) (Figure 2.1A), we anticipated this strain would produce only phosphorylated 
Ub and ion-exchange chromatography purification might be unnecessary. The yield of all 
pUb variants was increased 10 to 100-fold compared to the 1st generation pSer system 
(Table S2.1). In addition, several pUb variants (pUbS12, pUbS20, pUbS57) were all purified 
successfully (Figures 2.4C,D and S2.9C,E) at the milligram scale.  
Near-cognate decoding of UAG was reduced in BL21(DE3) compared to E. coli 
ΔRF1, but unphosphorylated Ub was still produced in BL21(DE3) (Figure 2.4C,D). For 
the unphosphorylated Ub produced by the UAG12 variant (Figure 2.4D, lanes 1 and 2), 
MS/MS identified Gln at the UAG encoded site (Figure S2.9D). All experiments showed 
that unphosphorylated Ub resulted from mistranslation. We found no evidence of 
dephosphorylation (i.e., Ser at UAG encoded loci). Maximal phosphoprotein production 
was observed in BL21(DE3) with the 2nd generation pSer system (300 µg·L-1 E. coli 
culture of pure pUbS20). In contrast, expression of the 2nd generation pSer system in E. 
coli ΔRF1 gave at most 8 µg·L-1 (Table S2.1). The data suggest that in E. coli ΔRF1, pSer 
incorporation efficiency is not the limiting factor for recombinant phosphoprotein 
synthesis. 
2.3.5 UAG codon skipping is a unique by-product of orthogonal translation 
Full protein ESI-MS of pUbS7 and pUblS65 revealed a third and unexpected protein 
species. For Ub, peaks corresponding to pUbS7 and Ub Gln7 (Figure 2.5A) were observed 
and confirmed by MS/MS (Figure 2.5B). Likewise, for the parkin Ubl domain, pUblS65 
and Ubl Gln65 were identified (Figure 2.6). However, in both cases signals 
corresponding to Ub lacking residue 7 (Figure 2.5A) and the Ubl domain lacking residue 
65 (Figure 2.6A) were also identified. This previously unknown interpretation of the 
UAG codon was verified by MS/MS (Figures 2.5D and 2.6D). Glu-C digestion of the 
UbΔ7 protein isolated by ion-exchange chromatography identified a peptide 
(NLYFQSNAMQIFVK6L8TGKTITLE) that resulted from peptidyl transfer between 
position 6 and position 8 of the Ub variant expressed with a UAG codon at position 7. 
Similarly, the UblΔ65 protein product was digested with trypsin and the resulting peptide 
(VQNCDLDQQ64I66VHIVQRPWR) confirmed deletion of the amino acid at position 65 
and formation of a peptide bond between positions Gln64 and Ile66. Because we 
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suspected this might result from a contaminating plasmid lacking the UAG locus, the Ubl 
expression plasmid was freshly transformed and 10 independent clones sequence 
verified, showing no evidence of a deletion of the codon in the plasmid. Two of these 
reverified Ubl UAG65 constructs were expressed with the pSer system in ΔRF1 E. coli. 
The Ubl domain Δ65 protein product was robustly reproduced (Figure S2.10).  
 
 
Figure 2.5: Codon skipping in a Ub variant with an in-frame UAG codon at position 7. (A) Full 
protein mass from ESI-MS run in positive ion mode (+0.1% formic acid) for the His6-pUbS7 variant shows 
peaks corresponding to translation of UAG as pSer, Gln, and as a single amino acid deletion (Δ7). Insertion 
of pSer (B) and Gln (C) in Ub at position 7 was confirmed by MS/MS run in positive ion mode (+0.1% 
formic acid). (D) MS/MS run in positive ion mode (+0.1% formic acid) of the Ub UAG7 construct also 
shows UAG was translated as a deletion. 
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To further investigate UAG codon skipping, we expressed the Ub UAG7 construct in 
E. coli ΔRF1 lacking specified components of the pSer system. MS/MS confirmed 
identity of the amino acids inserted at the UAG codon (Figure S2.11). Interestingly, the 
Ub Δ7 protein was only produced in the presence of the complete pSer system when 
exogenous pSer was added to the growth medium. Together, these results indicate that in 
E. coli ΔRF1, the UAG codon can be skipped or bypassed by the ribosome to yield 
proteins with a single residue deleted (UbΔ7 and UblΔ65). 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Codon skipping in a Ubl domain variant with an in-frame UAG codon at position 65. 
(A) Full protein mass from ESI-MS run in positive ion mode (+0.1% formic acid) for the pUblS65 variant 
shows peaks corresponding to translation of UAG as pSer, Gln, and as a single amino acid deletion (Δ65). 
Insertion of pSer (B) and Gln (C) in the Ubl domain at position 65 was confirmed by MS/MS run in 
positive ion mode (+0.1% formic acid). (D) MS/MS run in positive ion mode (+0.1% formic acid) of the 
Ubl domain UAG65 construct also shows UAG was translated as a deletion.  
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2.3.6 Parkin ligase activity is differentially modulated by pUb variants 
PINK1 is the upstream kinase known to phosphorylate Ub specifically at Ser65. Non-
covalent interaction of pUbS65 with parkin stimulates the ubiquitination activity of 
parkin10,11. In order to assess the integrity of genetically encoded pUbS65 to stimulate 
parkin ubiquitination activity, we compared its effect in auto-ubiquitination assays with 
PINK1 phosphorylated Ub (i.e., pUbS65-k, Figure 2.4A). Consistent with previous 
work10,11, we observed a significant enhancement of parkin auto-ubiquitination activity at 
a stoichiometry of 10% pUbS65 to 90% unmodified Ub. In addition, precise stoichiometric 
mixtures of 10% pUbS65 or 10% pUbS65-k to unmodified Ub (90%) led to essentially the 
same level of auto-ubiquitination activity (Figure 2.7A) that was, in both cases, enhanced 
over activity in the absence of pUb (Figure 2.7A). Similar reactions using either 10% 
pUbS12 or 10% pUbS20 (Figure 2.7B lane 2, C lane 4) did not stimulate parkin 
ubiquitination activity, indicating that the activation of parkin is specific for 
phosphorylation at position Ser65 in Ub. 
Interestingly, we found that assays conducted using pUbS65 or pUbS65-k as the only 
Ub source both displayed significant activation of parkin above the background level 
observed with unmodified Ub (Figure 2.7A) but lower than that observed using either 
10% pUbS65 or 10% pUbS65-k. This is in contrast to a previous report that indicated that 
100% pUbS65 is unable to stimulate parkin12. In order to differentiate between Ub chains 
built with Ub versus pUb, the unmodified Ub was His6-tagged, while His6-tag was 
removed from pUbS65. In experiments with 100% pUbS65, the Ub chains appeared at a 
lower molecular weight, indicating that these chains were synthesized from only the pUb 
species lacking the His6-tag. In lanes with 10% pUb
S65, the high molecular weight chains 
are dominant, indicating chains built with unmodified His6-Ub predominantly (Figure 
2.7A). 
In similar reactions, we monitored the abilities of pUbS12 or pUbS20 to be 
incorporated into Ub chains. We found that these variants do not stimulate parkin activity 
when included at low stoichiometry: pUbS12 (10% His6-pUb
S12 + 90% Ub; Figure 2.7B, 
lane 2) or pUbS20 (Figure 2.7C, lane 4). At high stoichiometry, no activity is observed 
with 100% pUbS20 (Figure 2.7C, lane 5), but the formation of at least a single His6-pUb
S12 
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ligated to parkin (at the expected molecular weight) suggests low parkin activity when 
pUbS12 is the only source of Ub in the reaction (Figure 2.7B, lane 3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Stoichiometry and location of Ub phosphorylation modulates parkin activity. (A) Parkin 
auto-ubiquitination assay with unmodified Ub (His6-Ub), PINK1 phosphorylated Ub (pUbS65-k) and 
genetically encoded pUbS65 were visualized by an anti-parkin immunoblot (M, molecular weight marker). 
Reactions all contain E1, E2, full-length parkin (E3), ATP and different Ub variants: 100% unmodified 
His6-Ub (lane 1), 10% pUbS65-k + 90% His6-Ub (lane 2), 100% pUbS65-k (lane 3), 10% genetically encoded 
pUbS65 + 90% His6-Ub (lane 4) and 100% genetically encoded pUbS65 (lane 5). (B) Auto-ubiquitination 
assay with Ub, pUbS65-k, and/or genetically encoded His6-pUbS12. The stoichiometry of Ub or pUb variants 
included in lanes 1–9 is listed above the blot. (C) Auto-ubiquitination assay with His6-Ub, pUbS65-k, and/or 
genetically encoded His6-pUbS20. The stoichiometry of Ub and pUb variants included in lanes 1–11 is listed 
above the blot. Triangles indicate decreasing stoichiometry of phosphorylation at positions 12 (B) and 20 
(C), respectively. In these experiments, the Ub His6-tag was cleaved with TEV protease except where 
indicated by the His6 prefix. 
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We then conducted experiments in the presence of 10% pUbS65-k to determine if 
stimulated parkin could use pUbS12 or pUbS20 as substrates. In the presence of 10% 
pUbS65-k with 90% pUbS12 or pUbS20, above background auto-ubiquitination bands were 
observable (Figure 2.7B lane 4; Figure 2.7C lane 6). Interestingly, these reactions both 
showed reduced activity compared to reactions lacking phosphorylation at S12 or S20. 
Decreasing the occupancy of phosphorylation at position 12 (Figure 2.7B) or at position 
20 (Figure 2.7C) led to concomitant increase in parkin activity. 
We also observed that Ub, pUbS12, pUbS20, and pUbS65 are all competent substrates 
for the E1 and E2 enzymes as evidenced by successful E2~Ub or E2~pUb conjugate 
formation (Figure S2.12). Taken together, the data suggest that Ub phosphorylation at 
positions 12 and 20 is disruptive to poly-Ub chain formation and may function as a 
negative regulator for parkin activity stimulated by pUbS65. Future experiments will show 
if this potential regulation is either by direct parkin inhibition or if these pUb variants are 
incompetent substrates for parkin. 
 Discussion 
2.4.1 Pure designer phosphoprotein 
Previous reports have shown it is possible to produce designer phosphoprotein in E. 
coli13,26, but the efficient production of pure phosphoprotein has remained challenging. 
We successfully produced several pUb variants in unambiguously pure form as 
evidenced by MS/MS and Phos-tag gels. Strikingly, in all conditions tested, we observed 
no dephosphorylation of the genetically encoded pUb variants.  
We found that optimization of the phosphoseryl-tRNA synthetase, and the E. coli 
host expression strain were factors that improved efficiency of phosphoprotein 
biosynthesis. E. coli ΔRF1 has been described as an ideal expression strain for UAG 
codon reassignment16. Ultimately, we found that BL21(DE3) is more efficient in 
phosphoprotein production. Despite competition between pSer insertion and RF1 in 
BL21(DE3), the fraction of phosphorylated protein produced was higher and BL21(DE3) 
grows to higher cell density compared to E. coli ΔRF115.  
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We observed mistranslation in both E. coli BL21(DE3) and ΔRF1, and 
mistranslation was evident with the less efficient (1st generation) and with the more 
efficient (2nd generation) pSer systems. Our goal in this study was not to necessarily 
maximize the yield of phosphoprotein. We17 (Table S2.1) and others11,22,26 have already 
produced phosphoproteins in sufficient amounts for biochemical and structural studies. 
Rather, we were concerned with demonstrating unambiguously and in a more rigorous 
fashion than previous reports that we indeed obtained pure phosphoprotein. Previous 
work relied on MS/MS identification of pSer in the phosphoprotein11,26, yet mistranslated 
protein may go undetected with this method. A modified pSer system11, including 
mutations in SepRS and the anticodon stem of tRNASep, recently reported similar mg·L-1 
culture yields of phosphoprotein as was previously reported for the 2nd generation pSer 
system26. While our yields were somewhat lower, we emphasize that we are reporting 
pure phosphoprotein yields, which likely reflect some loss of protein during column 
chromatography. We observed somewhat different efficiencies of protein production for 
different pUb variants. This is not unexpected and has been observed for other 
phosphoproteins15, potentially resulting from codon context or differential rates of protein 
folding or degradation.  
Our strategy enables streamlined and efficient production of phosphoproteins in E. 
coli at a scale of milligrams of pure phosphoprotein. Compared to chemical synthetic 
techniques (~ $5000 mg-1 phosphoprotein), our method enables any lab to economically 
biosynthesize (~ $50 mg-1 phosphoprotein reagent cost) pure phosphoproteins that are 
appropriate for biochemical, structural, and drug-screening applications. Importantly, this 
technology allows us to access any desired phosphorylation site without the need to 
identify and isolate active upstream kinases. 
2.4.2 Codon skipping 
Fascinatingly, in E. coli ΔRF1 pSer insertion competes not only with near-cognate 
translation with Gln but also with codon skipping. We have not observed codon skipping 
in BL21(DE3), which is RF1+ E. coli. However, we cannot rule out the possibility that it 
may occur at some level in other E. coli strains or naturally in living organisms. In two of 
the six phosphoproteins produced here, a significant amount of Ub or Ubl was produced 
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lacking the UAG-encoded residue. In both cases, protein product resulting from codon 
skipping includes a peptide bond between the residues encoded immediately before and 
after the UAG codon. We hypothesize that the ribosome underwent a +3 frameshift 
leading to a single in-frame amino acid deletion and a novel interpretation of the UAG 
codon. 
Aside from an obvious comparison to frameshifting27, the only other precedent for 
nucleotide skipping is from recent work in mitochondria of the yeast Magnusiomyces 
capitatus. In this case, the ribosome bypasses ~ 100 nucleotide intragenic untranslated 
regions (UTRs) in the mRNA and forms a peptide bond between the two residues 
encoded on either side of the UTR28. Together, these data indicate that genetic code 
expansion systems can produce unexpected translation products, and that the ribosome 
allows more flexible interpretations of the RNA message than previously envisioned. 
2.4.3 Parkin activity is sensitive to phosphorylation site location and 
stoichiometry 
Missense mutations in the human genes park6 (encoding the kinase PINK1) and park2 
(encoding parkin) are found in most cases of autosomal recessive juvenile 
parkinsonism29, yet the intricate interplay between these two proteins is only now being 
uncovered. Initial discoveries found that the PINK1 substrate is parkin itself, and 
phosphorylation at position Ser65 in the Ubl domain of parkin stimulated the E3 Ub 
ligase activity of parkin24. The parkin substrate Ub was later found to be a substrate of 
PINK1 as well, and pUbS65 stimulates parkin activity to a greater extent than 
phosphorylation of the Ubl domain7,8,30. In the current model for parkin activation, the 
Ubl domain is auto-inhibitory31, but phosphorylation of parkin at Ser65 leads to a weaker 
interaction of the Ubl domain with the RING1 domain of parkin, at least partially 
alleviating auto-inhibition, and activating parkin32. Similarly, PINK1 phosphorylation at 
Ser65 of Ub also activates parkin via pUbS65 binding with a conserved pSer-binding 
pocket on parkin, which induces a conformational change, causing release of the auto-
inhibitory Ubl domain32-35. Because continued PINK1 activity leads to both a release of 
autoinhibition and stimulation of parkin activity, this has been described as a feed-
forward signalling mechanism10. 
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Previous work found parkin activation by pUbS65 is dependent on the stoichiometry 
of phosphorylation, with 100% pUbS65 failing to activate Ub ligation12. Our data indicate 
that pUbS65 stimulates parkin activity at any stoichiometry. Some experiments presented 
here used what might be considered a ‘high stoichiometry’ of pUb, yet the stoichiometry 
and abundance of different pUb variants in the cell is not yet known. Quantitation of 
phosphoprotein abundance based on proteomic data suggests pUbS65 represents between 
0.1% and 20% of the total cellular Ub pool10,36,37. Recent data show that pUbS65 is not 
uniformly distributed in the cell. Rather, pUbS65 was shown by immunodetection to 
colocalize with parkin and the mitochondrial membrane38. The abundance of pUbS65 
increases with oxidative stress in cell-based studies and with age and PD status in patient 
tissue samples39. These data show that under disease-relevant conditions, the 
concentration of pUb in the vicinity of parkin might be much higher than is apparent 
from bulk measurements. Antibodies to image the distribution of other pUb variants are 
lacking. This is an exciting direction for future work that will be facilitated by the pUb 
variants produced here. 
Despite intense research on pUbS65, little is yet known about how other 
phosphorylation sites on Ub modulate parkin activity. Both traditional and high-
throughput proteomic investigations have identified variants of Ub phosphorylated at 
nearly all of its serine, threonine, or tyrosine resides40. This includes observations of 
pUbS20 41-43, in humans, mice, and rats3-6. Ours is the first report of Ub phosphorylation 
sites (distinct from pUbS65) that modulate the activity of an E3 Ub ligase. Our data show 
that phosphorylation of Ub at Ser12 or Ser20 led to pUb variants that are possibly less 
competent or incompetent substrates for parkin when compared with unmodified Ub or 
pUbS65. Since a system for site-specific incorporation of phosphothreonine has yet to be 
developed, pUbS12 was used to mimic phosphothreonine at position 12 in Ub. We 
hypothesize that these Ub phospho-sites may negatively regulate pUbS65-stimulated 
parkin in the cell. Indeed, phosphorylation sites on parkin itself (pS13144, pY14345) are 
known to negatively regulate its activity. Experiments with the other pUb variants 
produced here are currently underway. We anticipate that phosphorylation signalling on 
Ub may be a general mechanism for positively or negatively regulating the activity of the 
> 600 E3 Ub ligases in the human proteome. 
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 Conclusion 
There are > 100,000 experimentally documented phosphorylation sites in the human 
proteome46,47. Of these, at most only 100s of sites are annotated with a biological 
function48. It is estimated that human disease-causing missense mutations affect ~ 20,000 
distinct phosphorylation sites47. It is not surprising; therefore, that dysfunctional 
signalling is thought to drive major human diseases including cancers and 
neurodegeneration49,50. The ability to synthesize site-specifically phosphorylated proteins, 
such as pUb or recombinant active kinases13, enables drug-screening efforts to explore 
new targets and to specifically target pathological phosphorylation51. Our insights on 
pUbS65 activation of parkin may be useful pharmacologically, since small molecules that 
mimic this phosphorylated ubiquitin variant may activate parkin and benefit PD patients. 
Likewise, the possible inhibition of parkin by pUbS20 could potentially regulate the levels 
of constitutively active parkin in patients with pathogenic parkin mutations that disrupt 
parkin autoinhibition. In addition, site-specific phosphorylation of the mitogen-activated 
ERK activating kinase 1 to activate its downstream signalling partners showcases the 
usefulness of genetic code expansion systems to study the molecular mechanisms of 
disease13. We established an efficient route to pure recombinant phosphoprotein, and we 
have demonstrated that phosphoprotein purity is essential when enzyme activity depends 
critically on the site and occupancy of phosphorylation. 
 Supporting Information 
2.6.1 Supporting Methods 
Bacterial strains and plasmids. Recombinant proteins were expressed in BL21(DE3) 
(Invitrogen), or in E. coli ΔRF1 (C321.ΔA.exp, Addgene 49018) as specified. The 1st 
generation pSer system is on the plasmid pKD-pSer1 (Addgene 52054) that expresses 
SepRS, EFSep and 5 copies of the tRNASep expression cassette. The Ub expression 
plasmid (pDS0-Ub) was constructed using a T7 promoter, T7 terminator, and a cloning 
site (NdeI/BamHI) into an ampicillin-resistant backbone derived from pUC19. The Ub 
wild type gene was PCR amplified (PfuUltra II Fusion HS DNA polymerase, Agilent) 
from pET3a-His6TEVyUb
32 and inserted into pDS0 by restriction-free cloning. Quick-
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change mutagenesis was used (as described52) to generate Ub variants with in-frame TAG 
codons. DNA sequencing confirmed the correct Ub expression plasmids. pDS-pSer2 also 
contains 5 copies of the tRNASep expression cassette and is identical to pKD-pSer1 
except the SepRS and EFSep were mutated to their 2nd generation counterparts SepRS9 
and EFSep2126. 
Protein and phosphoprotein production. Either pKD-pSer1 or pDS-pSer2 and a pDS0-
Ub expression plasmid were freshly cotransformed into E. coli ΔRF1 (i.e., 
C321.ΔA.exp16) or BL21(DE3) cells and plated on lysogeny broth (LB)-agar plates with 
25 μg/mL kanamycin and 100 μg/mL ampicillin. Single colonies were picked to inoculate 
10 mL starter cultures in LB (with 100 μg/mL ampicillin and 25 μg/mL kanamycin), 
which were grown, shaking overnight at 37˚C. Once saturated, the starter culture was 
used to inoculate 1 L of LB media supplemented with ampicillin (100 µg/mL), 
kanamycin (25 µg/mL), and O-phospho-L-serine (pSer, 2.5 mM final concentration, 
Sigma-Aldrich). Cultures were grown at 37˚C until OD600 = 0.6. An additional 2.5 mM 
pSer was added to cultures at this point and the incubation temperature was reduced to 
16˚C. Protein expression was induced at OD600 of 0.8 by addition of 1 mM isopropyl β-
D-1-thiogalactopyranoside (IPTG) and continued for 18 hours at 16˚C.   
E1, E2, and E3 protein production and purification. Human Uba1 (E1), UbcH7 (E2), 
and Parkin (E3, full length) enzymes used in this study were produced and purified to 
homogeneity exactly as described previously32. PINK1 phosphorylated Ub (Ub pSer65k) 
was prepared by incubating wild type Ub with ATP and active Pediculus humanus GST-
PINK1 as described32. The PINK1 phosphorylated Ub was then purified by ion-exchange 
chromatography as below32.  
Affinity chromatography. Nickel affinity purification was performed using a gravity 
column with 1 mL Ni-NTA resin (Thermo Fisher Scientific, Waltham, MA, USA) per 
litre culture or a HisTrap FF column connected to the FPLC. For nickel affinity column 
chromatography by gravity, cleared lysate was loaded onto the column, washed 
extensively with wash buffer (50 mM Tris-HCl pH 8.0, 200 mM NaCl, 0.25 mM TCEP, 
50 mM NaF, 2 mM NaVO3 and 25 mM imidazole) and eluted with elution buffer (250 
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mM imidazole in wash buffer). For nickel affinity column chromatography by FPLC, 
cleared lysate was loaded onto the column at 0.5 mL/min, washed with 100 column-
volumes wash buffer, and eluted with 350 mM imidazole (in wash buffer). At this stage, 
TEV-protease was used to cleave the His6-tag from some of the Ub or pUb variants, as 
previously53. For some Ub variants the His6-tag was retained to differentiate Ub chains by 
molecular weight (as noted in Figures 2.4, 2.7 and S2.12). It is well established that the 
presence or absence of the His6-tag has no effect on the interaction of the Ub substrate 
with the E1, E2 or E3 enzymes involved in the parkin ubiquitination pathway (e.g.,53). 
Cation-Exchange chromatography. Purified Ub or Ubl domain proteins were separated 
on a 1 mL HiTrap SP-XL column (GE Healthcare) using a FPLC system (GE 
Healthcare). Prior to purification, samples were dialyzed overnight in buffer A (20 mM 
MES, pH 6.0). Cation-exchange chromatography was carried out at a flow rate of 0.3 
mL/min with a 1 hour gradient of 0-100% buffer B (20 mM MES, 200 mM NaCl, pH 
6.0). Phosphorylated protein species were collected in the unbound and flow-through 
fractions while the salt gradient eluted the non-phosphorylated species.  
Anion-Exchange chromatography. Purification was performed on a FPLC system (GE 
Healthcare) using a 1 mL HiTrap Q-HP (GE Healthcare) column equilibrated with buffer 
C (20 mM bis-tris propane, pH 8.7). Prior to purification, samples were dialyzed 
overnight in buffer C. Anion-exchange chromatography was performed at a flow rate of 
0.3 mL/min and 2 mL fractions were collected. Proteins were eluted using a 0-100% 
gradient of buffer D (20mM bis-tris propane, 500mM NaCl, pH 8.7) over 100 minutes. 
Cation- and anion-exchange chromatography were found to separate pUb from non-
phosphorylated Ub equally well. 
Phos-tag gels. Phos-tag acrylamide (Wako Pure Chemicals Ltd., Japan) was purchased 
and all Phos-tag gels were prepared according to manufacturer’s instructions with the 
following exceptions: ZnCl2 concentration was increased to 0.77 mM and gels were run 
at 25 mA per gel.  
Mass spectrometry. MS was performed both before and after ion-exchange 
chromatography. Samples were prepared for MS by overnight dialysis in 15 mM NH4 
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acetate to remove salt adducts. Whole protein ESI-MS was performed on a Q-Tof Micro 
mass spectrometer (Waters) equipped with a Z-spray source and run in positive ion mode 
(+0.1% formic acid). Samples were prepared for ESI-tandem-MS by digestion with 
trypsin or Glu-C protease. Briefly, 25 µg of protein was reduced with dithiothreitol and 
alkylated with iodoacetamide using standard protocols, followed by protease digestion 
using a 1:40 ratio of protease to sample. All mass spectrometry was performed at the 
Biological Mass Spectrometry Laboratory (The University of Western Ontario, 
http://www.uwo.ca/biochem/bmsl/).  
E2 loading assay. The assay was adapted from a previous study54 with modifications as 
follows. The reaction contained 0.5 μM E1 (Uba1), 20 μM E2 (UbcH7), 4 μM (Figure 
S2.12A) or 20 μM (Figure S2.12B) total Ub or pUb, and 10 mM ATP in reaction buffer 
containing 50 mM HEPES and 100 mM NaCl at pH 7.0. Reactions were incubated at 
37°C for 10 min. Samples were quenched with SDS non-reducing loading buffer 
(containing 50 mM EDTA) and incubated for 5 min at 100°C. The reaction products were 
separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and visualized by 
Coomassie staining. 
2.6.2 Supporting Tables 
Table S2.1: Pure phosphoprotein yields.  
1st generation pSer system is expressed from plasmid pKD-pSer117; 2nd generation pSer 
system is expressed from plasmid pDS-pSer2.  
Phosphoprotein 
variant 
E. coli expression strain pSer system pure pUb/L  
E. coli culture  
pUbS65 ΔRF1 (C321.ΔA.exp) 1st generation  11 µg/L 
pUblS65 ΔRF1 (C321.ΔA.exp) 1st generation 6 µg/L 
pUbS7 ΔRF1 (C321.ΔA.exp) 1st generation 0.1 µg/L 
pUbS57 ΔRF1 (C321.ΔA.exp) 1st generation 0.4 µg/L 
pUbS12 BL21(DE3) 2nd generation 78 µg/L 
pUbS20 BL21(DE3) 2nd generation 300 µg/L 
pUbS57 BL21(DE3) 2nd generation 25 µg/L 
pUbS65 BL21(DE3) 2nd generation 64 µg/L 
pUbS57 ΔRF1 (C321.ΔA.exp) 2nd generation 5 µg/L 
pUbS65 ΔRF1 (C321.ΔA.exp) 2nd generation 8 µg/L 
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2.6.3 Supporting Figures 
 
 
 
 
 
 
 
 
 
 
Figure S2.8: Production of the Ubl domain of Parkin (residues 1-76) phosphorylated at Ser65. (A) 
Coomassie-stained Phos-tag (top) and SDS-PAGE (bottom) gels show unmodified Ubl domain (lane 1), 
PINK1 phosphorylated and purified Ubl domain (lane 2), ion-exchanged purified genetically encoded 
pUblS65 (lane 3), and genetically encoded pUblS65 prior to ion-exchange chromatography showing a 
mixture of unphosphorylated Ubl and pUblS65 (lane 4). Phosphorylated proteins are retarded only in the 
Phos-tag gel (top) and not in the SDS-PAGE gel (bottom). 
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Figure S2.9: Purification of His6-pUbS57 and MS/MS data for His6-pUbS20 as well as His6-pUbS12. His6-
pUbS57 produced in E. coli ΔRF1 using the 1st generation pSer system led to pure His6-pUbS57 (lanes 4,5) as 
observed in Coomassie-stained (A) and immunoblotted (B, anti-His) Phos-tag gels. (C) MS/MS run in 
positive ion mode (+0.1% formic acid) identifies genetically encoded His6-pUbS20. (D) Unphosphorylated 
Ub produced along with His6-pUbS12 (Figure 2.4D) in BL21(DE3) from the Ub UAG12 construct was 
determined to contain Gln at the UAG encoded residue by MS/MS run in positive ion mode (+0.1% formic 
acid). (E) MS/MS run in positive ion mode (+0.1% formic acid) identifies genetically encoded His6-pUbS12. 
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Figure S2.10: Codon skipping resulting in the amino acid deletion at position 65 of the Ubl domain is 
reproducible. Full protein ESI-MS run in positive ion mode (+0.1% formic acid) for Ubl domain 
expressed from 3 independent clones (A-C) of the Ubl domain UAG65 consistently show protein product 
that corresponds to Ubl Δ65.  
48 
 
 
Figure S2.11: Specific conditions promote UAG codon skipping in E. coli ΔRF1. The His6-Ub UAG7 
construct was coexpressed with (A) pKD-SepRS/EFSep (containing the 1st generation SepRS/EFSep 
lacking tRNASep), (B) with pKD-pSer1 (containing SepRS/EFSep and 5 x tRNASep expression cassettes), 
or (C) with pKD-pSer1 in media supplemented with 5 mM exogenous pSer. Each strain yielded distinct 
protein products from translation of the UAG codon as Gln, pSer and/or a single amino acid deletion (Δ7), 
confirmed by MS/MS run in positive ion mode (+0.1% formic acid) of the purified and Glu-C digested Ub. 
To confirm reproducibility of codon skipping at position 7, panel C is from an independent protein 
purification from that shown in Figure 2.5B.  
49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2.12: E2 (UbcH7) loading assay with Ub and pUb variants. E2 loading assays were 
performed with unmodified Ub (A, B), pUbS12 (A), pUbS65-k (B), and His6-pUbS20 (B). The reaction at t 
= 0 (before ATP addition) shows only the E2 and Ub reactants. Following a 10-minute reaction, the 
appearance of an upper band indicates successful formation of the E2~Ub or E2~pUb conjugate. Bands 
representing free Ub, pUb or His6-pUb are indicated along with the E2, E2~Ub, E2~pUb, or E2~His6-
pUbS20 conjugates. 
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Chapter 3 
3 Parkin E3 ubiquitin ligase activity is stimulated by differentially 
phosphorylated ubiquitin variants 
Parkin is an E3 ubiquitin (Ub) ligase that is stimulated by phosphorylation of Ub at Ser65 
(pUbS65). The role of other phosphorylation sites on Ub and their respective kinases 
remain unknown. We used fluorescently labelled phosphorylated Ub (pUb) substrates to 
quantitatively relate the stoichiometry of Ub phosphorylation to parkin activation. We 
determined labeling efficiency and optimized the concentration of labelled-Ub required to 
visualize a broad range of parkin activity. The sensitivity of the fluorescence-based assay 
was demonstrated as we unexpectedly observed significant parkin activity when 
unmodified Ub was the only substrate. Fluorescence measurements indicate that pUbS65-
simulated parkin is 4-fold more active than autoinhibited and unstimulated parkin. We 
consistently observed a low level of parkin activity when pUbS12 is the only Ub variant in 
the reaction. Fluorescently labelled pUbS12 and anti-parkin immunoblots were used to 
identify two distinct parkin-pUbS12 linked chains following auto-ubiquitination of parkin. 
 Introduction  
Autosomal recessive juvenile parkinsonism is a familial form of Parkinson’s disease (PD) 
where mutations in park2 account for 50% of the observed cases in patients1. Parkin is an 
E3 Ub ligase encoded by park2 that has been implicated in clearing defective 
mitochondria from cells by tagging mitochondrial outer membrane proteins with polyUb 
chains2,3. Upon depolarization of mitochondrial membrane potential, the phosphatase and 
tensin homologue deleted on chromosome 10 (PTEN)-induced putative kinase 1 (PINK1) 
phosphorylates parkin at a particular serine residue (S65) within its Ub-like (Ubl) 
domain4. PINK1 also phosphorylates the homologous site, S65, in Ub5-8. The combined 
phosphorylation of both parkin and Ub leads to maximal activation of parkin E3 Ub 
ligase activity5-7,9. In PD patients, the role of parkin in clearing damaged mitochondria is 
disrupted1,2,10. 
Previously, it has been reported that pUbS65 fails to activate parkin when it is the only 
Ub variant present in the reaction8. Our recent findings demonstrated that pUbS65 
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activates parkin at any stoichiometry, including when it is the sole Ub variant (Figure 
2.7). In addition, we found that parkin activity is affected by the stoichiometry and 
location of phosphorylation in Ub11. Since the upstream kinases for several 
experimentally observed phosphorylation sites on Ub remain unknown, we used genetic 
code expansion strategies to site-specifically phosphorylate Ub at experimentally 
identified phosphorylation sites11-13. Our findings showed that pUbS12 partially activates 
parkin and that increasing the stoichiometry of pUbS20 inhibits pUbS65-stimulated parkin 
activity in a dose-dependent manner (Figure 2.7B,C). Activity of parkin was measured 
using auto-ubiquitination assays, which were visualized by immunoblotting with anti-
parkin to observe Ub chains built on parkin11. We found that anti-parkin immunoblots did 
not consistently report on parkin activity or enable quantitation of parkin activity.  
Here we produced fluorescently labelled and site-specifically phosphorylated Ub 
variants (Ub* and pUb*) to provide quantitative reports on parkin activity with distinct 
phosphorylation stoichiometry in the Ub substrate pool. We introduced a single cysteine 
(Cys) residue at the amino (N)-terminal of our Ub and pUb constructs to enable covalent 
linkage with small compounds, such as Alexa Fluors or DyLight dyes14. We used a 
sulfhydryl-reactive Dylight dye that relies on maleimide chemistry to produce Ub* and 
pUb*. Visualization of Ub* will allow direct measurement of Ub chains and enable more 
precise measurement of the stoichiometry of chain building on parkin15.   
 Materials and Methods 
3.2.1 Bacterial strains and plasmids 
Recombinant proteins were expressed in BL21(DE3) (Invitrogen, Carlsbad, CA, USA). 
The Ub expression plasmids used to make fluorescent Ub, pSG1-Ub* and pSG2-Ub*, 
were constructed by site-directed mutagenesis of N23C (as described16) in the N-terminal 
His6-tag linker sequence before the start site of Ub (i.e., -2 position) in the open-reading 
frame of pDS0-Ub (see Section 2.6.1) and pMCSG7-Ub, respectively. pMCSG7-Ub (a 
kind gift from Kathryn R. Barber, The University of Western Ontario) was constructed 
by ligation independent cloning of yeast Ub into pMCSG7 followed by site-directed 
mutagenesis of N23C in the -2 position. Site-directed mutagenesis was used (as 
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described16) to generate Ub variants with in-frame TAG codons. DNA sequencing 
confirmed the correct Ub* expression plasmids. pSG1-Ub* is the pUC19 backbone 
plasmid and pSG2-Ub* is pMCSG7 backbone plasmid. pDS-pSer2 is the plasmid 
containing the pSer system with SepRS9, EFSep21 and 5 copies of the tRNASep 
expression cassette (see Section 2.6.1). 
3.2.2 Ub overexpression and purification 
Expression plasmid pSG2-Ub* was freshly transformed into BL21(DE3) cells and plated 
on lysogeny broth (LB)-agar plates with 100 μg/mL ampicillin. Single colonies were 
picked to inoculate 10 mL starter cultures in LB (with 100 μg/mL ampicillin), which 
were grown, shaking overnight at 37˚C. Once saturated, the starter culture was used to 
inoculate 1 L of LB media supplemented with ampicillin (100 µg/mL). Cultures were 
grown at 37˚C until OD600 = 0.6 and the incubation temperature was reduced to 16˚C. 
Protein expression was induced at OD600 = 0.8 by addition of 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) and continued for 20 hours at 16˚C. 
Cells were harvested and resuspended in ~ 10 mL buffer A1 (50 mM Tris-HCl, 200 
mM NaCl, 0.25 mM TCEP, 25 mM imidazole, pH 7.5) per litre culture. 1 mM 
phenylmethylsulfonyl fluoride (PMSF) and 1 tablet of ethylenediaminetetraacetic acid 
(EDTA)-free mini protease inhibitor cocktail (Roche, Mississauga, ON, USA) were 
added to the cells. Cells were lysed using a French pressure cell press (Newport Scientific 
Inc, Jessup, MD, USA), centrifuged at 41,000 xg to remove cell debris, and filtered 
through a 1.2-µm filter for use on a gravity column. Nickel affinity purification was 
performed using a gravity column with 1 mL Ni-NTA resin (Thermo Fisher Scientific, 
Waltham, MA, USA) per litre culture. Cleared lysate was loaded onto the column, 
washed extensively with buffer A1 and eluted with buffer B1 (250 mM imidazole in 
buffer A1).  
Size-exclusion chromatography was performed on an AKTA Pure L1 fast protein 
liquid chromatography (FPLC) system (GE Healthcare, Little Chalfont, UK) using a 24 
mL Superdex 75 10/300 GL (GE Healthcare) column equilibrated with buffer C (25 mM 
HEPES, 100 mM NaCl, 0.5 mM TCEP, pH 7.0) to separate Ub from higher molecular 
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weight bacterial proteins. Size-exclusion chromatography was performed at a flow rate of 
0.1 mL/min and 0.5 mL fractions were collected. Ub eluted at approximately 0.5 column-
volumes of buffer C.  
3.2.3 pUb overexpression and purification 
Expression plasmids pDS-pSer2 and either pSG1-Ub* or pSG2-Ub* (with TAG at 
positions 12 and 65 of Ub) were freshly cotransformed into BL21(DE3) cells and plated 
on LB-agar plates with 25 μg/mL kanamycin and 100 μg/mL ampicillin. Single colonies 
were picked to inoculate 10 mL starter cultures in LB (with 100 μg/mL ampicillin and 25 
μg/mL kanamycin), which were grown, shaking overnight at 37˚C. Once saturated, the 
starter culture was used to inoculate 1 L of LB media supplemented with ampicillin (100 
µg/mL), kanamycin (25 µg/mL), and O-phospho-L-serine (pSer, 2.5 mM final 
concentration, Sigma-Aldrich). Cultures were grown at 37˚C until OD600 = 0.6. An 
additional 2.5 mM pSer was added to cultures at this point and the incubation 
temperature was reduced to 16˚C. Protein expression was induced at OD600 = 0.8 by 
addition of 1 mM IPTG and continued for 20 hours at 16˚C. 
Cells were harvested and resuspended in ~ 10 mL buffer A2 (50 mM Tris-HCl, 200 
mM NaCl, 0.25 mM TCEP, 50 mM NaF, 2 mM NaVO3, 25 mM imidazole, pH 8.0) per 
litre culture. 1 mM PMSF and 1 tablet of EDTA-free mini protease inhibitor cocktail 
(Roche, Mississauga, ON, USA) were added to the cells. Cells were lysed using a French 
pressure cell press (Newport Scientific Inc), centrifuged at 41,000 xg to remove cell 
debris, and filtered through a 1.2-µm filter for use on a gravity column. Nickel affinity 
purification was performed using a gravity column with 1 mL Ni-NTA resin (Thermo 
Fisher Scientific) per litre culture. Cleared lysate was loaded onto the column, washed 
extensively with buffer A2 and eluted with buffer B2 (250 mM imidazole in buffer A2).  
Size-exclusion chromatography was performed on a FPLC system (GE Healthcare) 
using a 24 mL Superdex 75 10/300 GL (GE Healthcare) column equilibrated with buffer 
C to separate pUb from higher molecular weight bacterial proteins. Size-exclusion 
chromatography was performed at a flow rate of 0.1 mL/min and 0.5 mL fractions were 
collects. pUb eluted at approximately 0.5 column-volumes of buffer C.  
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To separate pUb from non-phosphorylated Ub, anion-exchange chromatography was 
performed on an AKTA FPLC system (GE Healthcare) using a 1 mL HiTrap Q-HP (GE 
Healthcare) column equilibrated with buffer C (20 mM bis-tris propane, 250 μM TCEP, 
pH 8.7). Anion-exchange chromatography was performed at a flow rate of 0.1 mL/min 
and 1 mL fractions were collected. Proteins were eluted using a step-wise gradient of 
10%, 20%, 30%, 40% and 100% buffer D (20mM bis-tris propane, 500mM NaCl, 250 
μM TCEP, pH 8.7) for 10 column-volumes each.  
Effective separation of pUb from non-phosphorylated Ub was confirmed using Phos-
tag gels. Phos-tag acrylamide (Wako Pure Chemicals Ltd., Japan) was purchased and all 
Phos-tag gels were prepared according to manufacturer’s instructions with the following 
exceptions: ZnCl2 concentration was increased to 0.77 mM and gels were run at 25 mA 
per gel.  
3.2.4 Ub and pUb fluorescent labelling 
Cys-Ub and Cys-pUb variants were fluorescently labelled using Dylight 800 Maleimide 
(Thermo Fisher Scientific). Both Cys-Ub and Cys-pUb variants were dialyzed into buffer 
E (50mM HEPES, 100mM NaCl, 1mM EDTA, pH 7.0). After measuring the 
concentration of Cys-Ub (648 μM) and Cys-pUbS12 (38 μM) using the Bradford assay 
(Bio-Rad, Hercules, CA, USA), 100x excess of TCEP was incubated with the protein for 
15 minutes to ensure reduction of all intermolecular disulfide bonds. An excess of 5x 
Dylight 800 Maleimide dye (3.2 mM for Cys-Ub and 0.19 mM for Cys-pUbS12) was 
added to the reduced protein to create irreversible thioether linkages via maleimide 
chemistry and produce Ub* and pUb*. The reaction was quenched with 20x excess of 
dithiothreitol (DTT). Ub* and pUb* variants were dialyzed into storage buffer (50 mM 
HEPES pH 7.4) to remove unreacted dye and then stored at 4ºC.  
3.2.5 Quantitative auto-ubiquitination assays 
All reactions contained 0.1 µM E1 (Uba1), 1 µM E2 (UbcH7), 1 µM E3 (parkin), 5 mM 
ATP, and a 20 µM final concentration of Ub and/or pUb in a 10 µL final reaction volume 
incubated at 30°C for 1 h. Human Uba1, UbcH7, full-length parkin and PINK1 
phosphorylated Ub (Ub pSer65k) were produced and purified to homogeneity as 
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described previously15. The reaction buffer contained 5 mM MgCl2 and 50 mM HEPES 
pH 7.4. Reactions were quenched with sodium dodecyl sulfate (SDS)-loading buffer, 
resolved by 4-12% SDS-polyacrylamide gel electrophoresis (PAGE) (Life Technologies, 
Carlsbad, CA, USA) and analyzed by direct fluorescence monitoring using the Li-COR® 
Odyssey Infrared Imaging System at λ = 800 nm. The gels were then blotted on a PVDF 
membrane (Thermo Fisher Scientific) and immunodetected using anti-parkin primary 
antibody (Cell Signaling Technology, Danvers, MA, USA) and fluorescent-labelled 
secondary antibody (Thermo Fisher Scientific). Blots were prepared as previously 
described (see Section 2.2.3) and visualized using the Li-COR® Odyssey Infrared 
Imaging System at λ = 700 nm. 
 Results  
3.3.1 pUb production  
Ub is an 8.5 kilodalton (kDa) protein comprised of 76 amino acid residues17. Out of these 
76 amino acid residues, there are no Cys residues and few aromatic amino acid residues. 
A reduced number of aromatic amino acid residues make it difficult to observe Ub-
containing fractions on chromatograms from size-exclusion and anion-exchange 
chromatography since the spectrometer measures at a wavelength of 280nm18. The lack 
of Cys residues prevents facile fluorescent labelling of Ub19, a task that can be effective 
in quantitatively measuring chain building observed in activated parkin.  
In order to enable quantitation of pUbs involved in activating parkin, a single Cys 
residue was introduced in the -2 position of pUb to produce Cys-pUb. Initial attempts to 
purify Cys-pUb variants by size-exclusion chromatography were not completely 
successful (Figure 3.1). The wild-type Cys-Ub (Figure 3.2) and pUb variants (Figure 2.4 
B,D) were essentially pure, yet the Cys-pUbS65 and Cys-pUbS12 variants did not readily 
separate from higher molecular weight proteins (Figure 3.1).  
The use of the pUC19 backbone plasmid (pSG1-Ub*) to produce Cys-pUb was less 
efficient when compared to previously obtained pUb yields (Table S2.1), even though the 
only variation was the introduction of a single Cys residue. We switched to the pMCSG7 
backbone plasmid (pSG2-Ub*) to produce Cys-pUb since this route expressed wild-type 
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Cys-Ub considerably better with yields of 360 μg per litre Escherichia coli (E. coli) 
culture (Figure 3.2). However, purification of Cys-pUbS65 and Cys-pUbS12 with the 
pMCSG7 backbone plasmid did not separate completely by size-exclusion 
chromatography (Figure 3.1C,D). 
 
 
 
 
Figure 3.1: Ineffective separation of Cys-pUbS65 and Cys-pUbS12 by size-exclusion 
chromatography. Lanes show molecular weight marker (M) followed by elution fractions from size-
exclusion chromatography resolved by Coomassie-stained SDS-PAGE gels of (A) Cys-pUbS65 and (B) 
Cys-pUbS12 produced using the pUC19 backbone plasmid (pSG1-Ub*), and (C) Cys-pUbS65 and (D) 
Cys-pUbS12 produced using the pMCSG7 backbone plasmid (pSG2-Ub*) plasmid. His6-Cys-pUb has a 
molecular weight of 11.2 kDa (indicated by ).  
Figure 3.2: High yield and purity of Cys-Ub observed in nickel-affinity column chromatography 
elution fractions. Lanes show molecular weight marker followed by elution fractions from nickel-
affinity column chromatography of Cys-Ub. His6-Cys-Ub has a molecular weight of 11.2 kDa 
(indicated by ).  
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3.3.2 Fluorescent labelling of pUb  
The Cys-pUb variants were not produced in high yield (1.15 μg per litre E. coli culture 
for Cys-pUbS65 and 2.14 μg per litre E. coli culture for Cys-pUb12) in the pUC19 
backbone plasmid. The yield of Cys-pUbS65 using the pUC19 backbone plasmid was not 
sufficient so this Cys-pUb variant was not labelled. However, both Cys-Ub and Cys-
pUbS12 were purified successfully (Figures 3.2 and 3.3A) and labelled using Dylight 800 
Maleimide (Figure 3.3B). By maintaining the pH between 6.5-7.5, the maleimide group 
present in the dye can react with sulfhydryl groups present on the Cys residue in Cys-Ub 
or Cys-pUb to create irreversible thioether linkages and generate Ub* and pUb* 19. The 
concentration of protein loaded on the gel was not consistent when the efficiency of 
labelling was measured due to underestimation of the concentration of Ub* in lane 2 
(Figure 3.3B). This was accounted for when performing auto-ubiquitination assays using 
Ub* and pUbS12*. 
 
 
 
 
3.3.3 Quantitation of pUb stimulation 
Initially, auto-ubiquitination assays were performed using Ub* to confirm activation of 
parkin in the presence of 10% unlabelled pUbS65 (Figure 3.4). It is evident that 
unstimulated parkin forms Ub* chains in the presence of 100% Ub*. Parkin is activated 
to a greater extent in the presence of 10% pUbS65 as seen by increased Ub* chain 
Figure 3.3: Production of Ub* and pUbS12*. (A) Phos-tag gel shows unmodified Ub (lane 1) and Cys-
pUbS12 (lane 2). (B) Ubinfrared (UbIR)scan shows labelling efficiency of and pUbS12* and Ub*. 
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formation (Figure 3.4A) and the increase in densitometry (Figure 3.4B). This is 
consistent with our previous findings as well as finding from other groups8,11. Increasing 
the concentration of parkin in the reaction from 1µM to 2µM did not show a significant 
increase in activity. In addition, incubation times of both 60 minutes and 90 minutes at 
30ºC showed that parkin is 4-fold more active in the presence of 10% pUbS65-k than in the 
presence of 100% unmodified Ub* (Figure 3.4B).  
We then investigated the impact of 100% pUbS12* on parkin activity in auto-
ubiquitination assays (Figure 3.5A). The Ubinfrared (UbIR) scan, which observes Ub 
fluorescence at λ = 800 nm, together with the anti-parkin immunoblot revealed the 
presence of two parkin-pUbS12 bands (Figure 3.5A,B lane 3). This is consistent with our 
previous anti-parkin immunoblot (Figure 2.7B) since partial activation of parkin was 
previously observed in the presence of 100% pUbS12. In these reactions only pUbS12 was 
fluorescently labeled (Figure 3.5A). As a result, only chains built with pUbS12 are visible 
(Figure 3.5A), while all parkin-conjugated Ub chains are observable in the anti-parkin 
immunoblot (Figure 3.5B). Control lanes 1 and 2 lack fluorescently labeled Ub (Figure 
3.5A). The corresponding anti-parkin immunoblot confirms significant activation of 
Figure 3.4: Ub* is an effective tool to quantitate parkin activity. (A) Parkin auto-ubiquitination assays 
with fluorescently labelled unmodified Ub (Ub*) and PINK1 phosphorylated Ub (pUbS65-k) were 
visualized by IR scan at λ=800 nm. Reactions all contain E1, E2, full-length parkin (E3), ATP and 
different Ub variants. The stoichiometry of Ub* and pUbS65-k included in lanes 1-8 are listed below the gel. 
The reaction time and amount of parkin used in the reactions are listed above the gel. (B) The 
representative densitometry graph of the gel in A. 
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parkin observed with pUbS65-k (Figure 3.5B, lane 1) and reduced but evident activity with 
100% unmodified Ub (Figure 3.5B, lane 2). 
Further testing of pUbS12 at different stoichiometries revealed parkin activation in the 
presence of 30% pUbS12 (Figure 3.5C, lane 4) similar to patterns seen in auto-
ubiquitination assays where pUbS12 was present in mixtures with unmodified Ub and 10% 
pUbS65 (Figure 2.7B, lanes 4-9). The Ub or pUb variant responsible for the chain building 
observed in these mixtures is inconclusive at this point. In future work, we will extend 
these studies to test auto-ubiquitination activity of parkin with precise stoichiometric 
mixtures of fluorescently labelled and unlabelled Ub, pUbS65-k and pUbS12 (as in Figure 
2.7B, lanes 4-9 and Figure 3.5C, lane 4). Controls used in the anti-parkin immunoblot 
Figure 3.5: pUbS12 partially activates parkin in auto-ubiquitination assays. (A) Parkin auto-
ubiquitination assays with unmodified Ub (Ub), PINK1 phosphorylated Ub (pUbS65-k) and fluorescently 
labelled pUbS12 (pUbS12*) were visualized by IR scan at λ=800 nm (M, molecular weight marker). 
Reactions all contain E1, E2, full-length parkin (E3), ATP and different Ub variants: 10% pUbS65-k + 
90% Ub (lane1), 100% unmodified Ub (lane 2) and 100% pUbS12* (lane 3). (B) Parkin auto-
ubiquitination assays with Ub (Ub), PINK1 phosphorylated Ub (pUbS65-k) and fluorescently labelled 
pUbS12 (pUbS12*) were visualized by anti-parkin immunoblot (M, molecular weight marker). The 
stoichiometry of Ub and pUb variants included in lanes 1-3 are the same as in (A) and are listed below 
the blot. (C) Parkin auto-ubiquitination assays with unmodified Ub (Ub), PINK1 phosphorylated Ub 
(pUbS65-k) and pUbS12 were visualized by anti-parkin immunoblot (M, molecular weight marker). The 
stoichiometry of Ub and pUb variants included in lanes 1-5 are listed below the blot. 
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confirm activation of parkin by both 10% pUbS65-k (Figure 3.5C, lane 2) and 100% 
pUbS65-k (Figure 3.5C, lane 5), with reduced chain building by autoinhibited and 
unstimulated parkin (Figure 3.5C, lane 1). 
We further optimized the fluorescent parkin assay by decreasing the amount of 
fluorescently labelled Ub in the reaction mixture in order to determine the optimal level 
of labelled Ub needed to clearly visualize and quantitate parkin activation. Auto-
ubiquitination assays were performed with 100% pUbS12 where 25% of the mixture was 
pUbS12* and the remaining 75% was unlabelled pUbS12 (Figure 3.6A, lane 1). The assay 
was also performed with 100% pUbS12 where 10% of the mixture was pUbS12* and the 
remaining 90% was unlabelled pUbS12 (Figure 3.6A, lane 2). In both cases, only one band 
was observed unlike the intense double banding pattern seen previously in auto-
ubiquitination assays with only labelled pUbS12* substrate (Figure 3.5A, lane 3). 
Similarly, unmodified Ub was not sufficient to observe parkin-Ub chain building when 
only 10% of the mixture was Ub* (Figure 3.6A, lane 3 and 4). The data show ideal 
reaction conditions require Ub or pUb variant that is completely labelled and at a minimal 
concentration of 20 μM to observe phosphorylation-dependent modulation of parkin 
activity in auto-ubiquitination assays (Figures 3.4, 3.5A and 3.6A).  
The corresponding anti-parkin immunoblot does not discriminate between the 
presence or absence of fluorescent labels (Figure 3.6B) since the blot shows similar 
parkin activity levels to those observed previously in the case of 100% pUbS12, 100% Ub 
and 10% pUbS65-k (Figure 3.6B, lanes 1-4). It is important to note that significant activity 
was seen with 90% Ub* and 10% pUbS65-k in the UbIR scan (Figure 3.6A, lane 6). In the 
corresponding anti-parkin immunoblot, the activity of parkin seems to appear near the 
level of unstimulated parkin in the presence of 90% Ub* and 10% pUbS65-k (Figure 3.6B, 
lane 6). Inconsistencies seen with the anti-parkin immunoblots, which are not uncommon, 
in auto-ubiquitination assays highlight the importance of the use of Ub* and pUb* 
variants. 
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3.3.4 Enhancing Cys-pUbS12 production and purification 
All auto-ubiquitination assays were done with pUbS12* purified from the pUC19 
backbone plasmid. However, the Cys-Ub was purified from the pMCSG7 backbone 
plasmid and was produced in significantly higher yield (360 μg per litre E. coli culture 
for Cys-Ub) (Figure 3.2). Therefore, we switched the production of Cys-pUbS12 to the 
pMCSG7 backbone plasmid. Since the pUbS65 in auto-ubiquitination assays was 
previously produced using the kinase PINK1 and not fluorescently labelled, we used the 
pMCSG7 backbone plasmid to produce Cys-pUbS65 as well.  
Although, incomplete purification was observed following size-exclusion 
chromatography of Cys-pUbS12 and Cys-pUbS65 using the pMCSG7 backbone plasmid 
(Figure 3.1C,D), these Cys-pUb variants were subjected to anion-exchange 
chromatography (Figure 3.7). We found that pUb was the dominant band in the Phos-tag 
gels, but anion-exchange chromatography did not completely separate Cys-pUbS12 or 
Cys-pUbS65 from non-phosphorylated Cys-Ub. We suspected the formation of disulfide 
Figure 3.6: Optimizing the concentration of fluorescently labelled Ub or pUb variants in auto-
ubiquitination assays. (A) Parkin auto-ubiquitination assays with unmodified Ub (Ub and Ub*), 
PINK1 phosphorylated Ub (pUbS65-k), pUbS12 and pUbS12* were visualized by IR scan at λ=800 nm (M, 
molecular weight marker). Reactions all contain E1, E2, full-length parkin (E3), ATP and different Ub 
and pUb variants in stoichiometry as listed below the gel. (B) Replicated parkin auto-ubiquitination 
assays (identical reactions as in A) visualized by anti-parkin immunoblot. 
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bonds between Cys-pUb and mistranslated Cys-Ub led to incomplete pUb purification. 
We added reducing agent (250 μM TCEP) during this purification step, and this led to 
essentially pure pUb (Figure 3.7). 
  
 
 
 
 
 Discussion 
3.4.1 Fluorescently labelled phospho-ubiquitin is a chemical probe for 
elucidating signalling pathways 
Ub* has been previously employed to study the autoinhibitory Ubl domain of parkin15. 
This method proved to be more efficient as observed by the distinct chain building on 
parkin as opposed to the use of anti-parkin immunoblots to study the effect of the Ubl 
domain15,20. Ub* also has a wider range of applications since it can be used to determine 
enzyme kinetics of parkin through time-course measurements and varying concentrations 
of substrate.  
Previously, we were able to successfully produce several pUb variants in pure form 
as demonstrated by MS/MS and Phos-tag gels11. These variants were used in auto-
ubiquitination assays that were visualized on anti-parkin immunoblots to test their effect 
Figure 3.7: Nearly complete separation of Cys-pUbS65 and Cys-pUbS12 by anion-exchange 
chromatography. Lanes show unmodified Ub as the negative control followed by elution fractions 
from anion-exchange chromatography resolved by Coomassie-stained Phos-tag gels of (A) pUbS65 and 
(B) pUbS12 produced using the pMCSG7 backbone plasmid. Migration of Ub and pUb are shown beside 
the gels.  
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on parkin activation11. Here we optimized a quantitative method to monitor parkin 
activity with fluorescently labelled Ub and pUb variants. 
Since Ub does not contain any internal Cys residues, we introduced a single Cys 
residue in the -2 position to allow specific labelling of the single free sulfhydryl group by 
maleimide chemistry. Introduction of a single Cys residue reduced the purity of pUb 
variants significantly by hindering separation of pUb variants from higher molecular 
weight proteins. A possible explanation is conformational change in the pUb variant 
preventing dissociation from bacterial proteins or disulfide bond formation between the 
Cys-pUb variant and other proteins. Addition of increasing amounts of reducing agent 
(i.e., TCEP) or switching to an alternate reducing agent (i.e., DTT) could overcome this 
issue in the future. Future experiments will also enable elucidation of the role the Cys 
residue plays in obstructing pUb separation.  
3.4.2 pUbS65 and pUbS12 represent different routes to stimulate parkin 
Mutations in park2 (the gene encoding parkin) were identified in 50% of AR-JP patients, 
and defective parkin is thought to be the primary cause of AR-JP1,10. It was only recently 
discovered that PINK1 is recruited to the mitochondria during oxidative stress to activate 
parkin E3 ligase activity by phosphorylating parkin at S65 in the Ubl domain2-4. PINK1 
was also found to phosphorylate the homologous site, S65, in Ub to stimulate parkin 
activity5-8. The exact mechanism of parkin activity is still undefined. Initially, pUbS65-
induced parkin activation was found to be dependent on the stoichiometry of 
phosphorylation, with parkin showing no activity when pUbS65 was the sole Ub variant8. 
Our previous studies demonstrate unambiguously that pUbS65 stimulates parkin activity at 
any stoichiometry11.  
The use of fluorescently labelled Ub and pUb is an effective method to identify the 
substrate responsible for chain building during parkin activation. This provides further 
insight into the mechanism of parkin activation as currently proposed models are 
contradictory5-7,9. Some studies suggest that PINK1 phosphorylates parkin and Ub, which 
then proceeds to relieve autoinhibition and stimulate parkin leading to a feed-forward 
model of parkin activation5,7. Other studies suggested phosphorylation of parkin primes 
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the enzyme for activation by pUbS65 6,9. Although there has been considerable amount of 
research on pUbS65, there is not much evidence for the effect of other experimentally 
observed phosphorylation sites of Ub on parkin12,13. Studies with pUbS20 and pUbS57 
found that these pUb variants fail to simulate parkin9. We found that stimulated parkin 
activity is reduced in a dose-dependent manner with increasing phosphorylation levels of 
pUbS20 in the Ub substrate pool and that pUbS12 can ubiquitinate parkin11.  
In this study, we found that unmodified Ub can stimulate parkin and pUbS65 
significantly activates parkin in fluorescent auto-ubiquitination assays. We also observed 
a low level of clearly defined parkin activity with pUbS12 as the only Ub variant in the 
reaction. Since a system for site-specific incorporation of phosphothreonine has yet to be 
developed, pUbS12 was used to mimic phosphothreonine at position 12 in Ub. In a 
mixture of unmodified Ub and pUbS12, parkin was activated as well, but to a greater 
extent than when pUbS12 was the only Ub variant. In addition, fluorescently labelled 
unmodified Ub showed more Ub chain building than pUbS12. We also observed that 
fluorescently labelled Ub or pUb variants is a more consistent method of determining 
parkin activity in auto-ubiquitination assays when compared with anti-parkin 
immunoblots. However, ideal auto-ubiquitination assay conditions require completely 
labelled Ub or pUb variant that is at a minimal concentration of 20 μM to observe 
phosphorylation-dependent modulation of parkin activity. 
In all cases, pUbS65 showed the highest activation of parkin as seen by increased 
chain building from fluorescently labelled unmodified Ub. We propose that increased 
amounts of pUbS12 in the cell could perturb pUbS65-induced activation of parkin, which is 
required for targeting mitochondrial outer membrane proteins for degradation. 
Experiments with precise ratios of fluorescently labelled Ub and pUb variants are 
currently underway to determine the exact stoichiometry of chain building on parkin 
when Ub and pUb variants are present in different ratios in the same reaction mixture. 
The varying effects of different phosphorylation sites on Ub towards parkin activation 
suggest that phosphorylation of Ub may be a signal for regulation of parkin and possibly 
other E3 Ub ligases in the human proteome. 
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 Conclusion 
Of the 100,000 experimentally observed phosphorylation sites in the human proteome, 
the upstream kinase for more than 90% of these sites remains unknown13,21. Parkin 
activity depends on the location and stoichiometry of phosphorylation on its substrate Ub. 
Site-specific phosphorylation of proteins, such as Ub, enables identification of new routes 
to parkin activation. Identification of alternate routes of phosphorylation-dependent 
activation of proteins involved in disease, such as parkin in PD, can provide insight into 
the molecular mechanism of PD. We demonstrated that differentially phosphorylated Ub 
molecules are characteristically distinct or, in comes cases, incompetent substrates for 
parkin.  
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Chapter 4 
4 Summary and future perspectives  
 Experimental summary 
4.1.1 Goal 
Upon oxidative stress in the mitochondria, the phosphatase and tensin homologue deleted 
on chromosome 10 (PTEN)-induced putative kinase 1 (PINK1) phosphorylates parkin at 
a specific serine residue (S65) in its ubiquitin (Ub)-like (Ubl) domain and the 
homologous site, S65, in the parkin substrate Ub1-5. These phosphorylation events disrupt 
the autoinhibition on the E3 Ub ligase parkin and primes the enzyme for activation1,2,4,6. 
There are 6 other experimentally determined phosphorylation sites on Ub (T7, T12, T14, 
S20, S57 and Y59) for which the upstream kinases remain unknown7,8. These sites are 
not proteomic artifacts, but genuine phosphorylation sites conserved from yeast to 
human7. Ub phosphorylation sites seen by high-throughput proteomic data were verified 
using several different phosphoproteomic methods7. The overall goal of this thesis was to 
identify novel routes of parkin activation by producing site-specifically phosphorylated 
Ub (e.g., pUbS12 and pUbS20).  
Genetic code expansion is an effective method to produce site-specifically 
phosphorylated proteins in Escherichia coli (E. coli)9. Site-specific phosphoprotein 
production using genetic code expansion is essential when the upstream kinases are 
unknown or when it is difficult to produce phosphoproteins in active form. Production of 
pUb at two previously uncharacterized sites (T12 and S20) was achieved in high yield 
and high purity using genetic code expansion. Several other experimentally determined 
phosphorylation sites on Ub (T7 and S57) were also produced in pure form.  
Due to low protein yields from competition between peptide chain elongation with 
the aminoacylated suppressor tRNA and termination by release factor 1 (RF1), a RF1 
deficient E. coli strain was engineered9-14. The RF1 deficient E. coli strain had an 
increased O-phospho-L-serine (pSer) incorporation efficiency per cell, but was found to 
be toxic to cell fitness and viability15. Genetic code expansion strategies, such as the pSer 
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system, do not have the same fidelity as the canonical protein synthesis since 
mistranslation is a common by-product especially in RF1 deficient E. coli16.  Near-
cognate mis-incorporation of glutamine was most commonly observed, and mis-
incorporation of lysine, tyrosine and glutamic acid were present in lower abundance than 
pSer16.  
Codon skipping was a novel product of mis-translation observed during production 
of pUb variants using the pSer system in RF1 deficient E. coli cells. During purification 
of pUbS7, we observed a +3 frameshifted protein (Δ7) that completely skipped the in-
frame UAG codon. Codon skipping was also observed during purification of the Ubl 
domain of parkin phosphorylated at Ser65. However, simple purification procedures led 
to separation of pure phosphorylated Ub and Ubl from mis-translated proteins. We 
identified that for single pSer incorporation, the 2nd generation pSer system and 
BL21(DE3) cells are ideal for expression. 
Precise stoichiometric measurements of pUbs needed to stimulate parkin E3 Ub 
ligase activity were also determined using high purity pUbs. Stimulated parkin was 
inhibited in a dose-dependent manner by pUbS20 (Chapter 2) and unstimulated parkin was 
partially activated by pUbS12 (Chapter 2 and 3). In addition, pUbS65 was found to be a 
suitable substrate for parkin at all stoichiometries, and our fluorescence assay uncovered 
that unstimulated parkin showed significant activity when unmodified Ub is the only 
source of Ub in the reaction. 
4.1.2 Limitations 
The limitations to site-specific production of pUbs that are previously uncharacterized is 
potential interactions with other proteins and changes in folding compared to wild-type 
Ub. Introduction of the cysteine residue at the -2 position of Ub could also create 
previously absent interactions. During purification of several pUb variants, unsatisfactory 
separation was observed: Cys-pUbS12 and Cys-pUbS65 did not separate from higher 
molecular weight E. coli proteins. Increasing the amount of reducing agent allowed 
separation and produced essentially pure Cys-pUbs. Likewise, the production of pUbS12 
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and pUbS20 in high yield and high purity provided key insights and uncovered novel 
alternate routes to parkin activation.  
 Future Directions 
4.2.1 Potential therapeutic agents for parkin 
The activation of parkin by pUbS65 is widely studied due to the discovery of its upstream 
kinase, PINK1. Here, we demonstrate the first potential inhibitor to parkin. It is well-
known that the Ubl domain autoinhibits parkin in cis. However, there has been no 
observation of parkin inhibition by a molecule in trans. We found that increasing 
phosphorylation of pUbS20 inhibits parkin activity, which implicates this phosphorylated 
form of Ub to be the first inhibitor to parkin. Although we need to do additional 
experiments to validate our findings, preliminary data suggests pUbS20 as the only 
potential parkin inhibitor to date. Through auto-ubiquitination assays, pUbS20 prevents 
stimulation of parkin in a dose-dependent manner (Figure 2.7C). We recognize that in 
vivo studies must be performed to validate these in vitro results, but this thesis has made 
key advances in providing the first assignment of function to a Ub phosphorylation site 
other than S65. These data suggest that Ub phosphorylation may represent a new tool to 
control parkin activity. Our fluorescently labelled pUb variants are, therefore, chemical 
probes of the parkin pathway and represent a starting point for future drug therapy to 
modulate stimulation of parkin during mitochondrial membrane potential depolarization. 
In addition, activation of parkin when pUbS65 or pUbS12 are the sole Ub variants in the 
reaction suggests potential alternate routes to mitophagy (Figure 2.7A,B). Small 
molecules that mimic the structure of pUbS65 or pUbS12 could both potentially be used to 
control the activity of parkin in parkin-linked Parkinson’s disease (PD) patients.   
4.2.2 Crystallization of phospho-ubiquitin variants 
Further mechanistic insight into the activation – or lack thereof – of parkin can be 
obtained through crystal structure determination. Since the pUb variants have different 
effects on parkin activation, deciphering the crystal structure of pUbs and pUb-parkin 
complexes will provide insight into the location of parkin binding or the structural 
hindrance preventing parkin from binding. The work presented in this thesis suggests 
76 
 
direct interactions between parkin and pUbS12, and potential interactions between parkin 
and pUbS20. Structural data is currently lacking in this area, so this represents an exciting 
future direction. 
4.2.3 Phospho-ubiquitin interactome 
Production of pure pUb can also help identify potential phosphorylation-dependent Ub 
interactors through pull-down assays and pUb-interactor identification by mass 
spectrometry. The pull-down assays can be done with human embryonic kidney (HEK)-
293 cells or SH-SY5Y neuronal cells. One recent example shows that pull-down assays 
done with the phosphomimetic S65E improves the interaction between Ub and Rad23, 
and thus results in a possible inactivation of Rad23’s ability to shuttle proteins for 
proteasomal degradation17. It is thought that Rad23 would eventually be depleted from 
cells leading to increased Ub conjugates resulting from reduced substrate processing17. 
Protein interactions of the other experimentally determined pUb variants are yet to be 
explored and represent an exciting area for future research. 
 Conclusion 
This thesis provides insight into the roles of additional phosphorylation sites on Ub as 
potential substrates for parkin. Although the upstream kinases for many of these sites 
were unknown, genetic code expansion strategies were employed to site-specifically 
phosphorylate desired sites on Ub so that the stoichiometry and location of 
phosphorylation can be controlled in precise experiments monitoring parkin activity. 
Elucidation of the roles of additional phosphorylation sites in Ub provides insight into 
signalling in the ubiquitin proteasome system, suggests potential drug targets and 
ultimately future therapies for the treatment of PD. The downstream signalling effects of 
phosphorylated Ub can uncover new nodes for potential therapeutic intervention in PD-
related pathways. 
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